Pasar al contenido principal

Inhibidores de carbapenemasas: actividad frente a Enterobacterales productores de carbapenemasas, mecanismos e impacto en la evolución de la resistencia antimicrobiana (PROTECT)

PI22/01212

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Salud
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PROFESOR NOVOA SANTOS
Centro realización FUNDACION PROFESOR NOVOA SANTOS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Emergence of KPC-producing Pseudomonas aeruginosa in Spain: insights into an outbreak and resistance to the novel carbapenem/β-lactamase inhibitor combinations imipenem/relebactam and meropenem/vaborbactam

  • Pérez-Rodríguez, Gloria
  • Aja-Macaya, Pablo
  • González-Pinto, Lucía
  • Taltavull, Biel
  • Tarriño-León, María
  • Gallardo-García, María del Mar
  • Blanco Martín, Tania
  • Rodríguez-Pallares, Salud
  • Sánchez-Peña, Lucía
  • Moscoso, Miriam
  • Beceiro Casas, Alejandro
  • Oliver, Antonio
  • Bou, Germán
  • Arca-Suárez, Jorge
[Abstract] We report an outbreak of KPC-producing Pseudomonas aeruginosa in Spain, involving four patients and an environmental isolate recovered from a hospital sink. All isolates belonged to clone ST253 and exhibited difficult-to-treat resistance, including resistance to imipenem/relebactam and meropenem/vaborbactam. Genomic analysis confirmed a plasmid-encoded blaKPC-2 and OprD deficiency. Functional assays demonstrated synergy between KPC-2 production and porin loss on resistance to carbapenem/β-lactamase inhibitors. The findings highlight the clinical threat posed by KPC-producing P. aeruginosa., This study was supported by the Instituto de Salud Carlos III (ISCIII), through projects PI22/01212, PI23/00851, PI24/00010, and PI24/00920, and co-funded by the European Union. The research was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC, CB21/13/00055, and CB21/13/00099). Funding was also provided by Axencia Galega de Innovación (GAIN), Consellería de Innovación and Consellería de Economía, Emprego e Industria, and Xunta de Galicia (IN607D 2021/012 to A.B., IN607A 2024/009 to G.B., and IN607D 2024/008 to J.A.-S.). G.P.-R. was financially supported by GAIN-Xunta de Galicia (IN606A 2025/020). L.G.-P. was financially supported by the ISCIII PFIS program (FI23/00074). T.B.-M. was financially supported by the ISCIII Río Hortega program (CM23/00095). S.R.-P. was financially supported by the ISCIII Río Hortega program (CM23/00104). L.S.-P. was financially supported by GAIN-Xunta de Galicia (IN606A 2024/022). M.M. was financially supported by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC). J.A.-S. was financially supported by the ISCIII Juan Rodés program (JR21/00026). This work was also supported by the Fundación Pública Galega de Investigación Biomédica INIBIC, which provided financial support for the final publication of the article.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance in Pseudomonas aeruginosa

  • González-Pinto, Lucía
  • Monge-Olivares, Laura
  • Pérez-Rodríguez, Gloria
  • Aja-Macaya, Pablo
  • Sánchez-Peña, Lucía
  • Gomis-Font, María Antonia
  • Rodríguez-Pallares, Salud
  • Blanco Martín, Tania
  • López-Cerero, Lorena
  • Beceiro Casas, Alejandro
  • Bogaerts, Pierre
  • Oliver, Antonio
  • Bou, Germán
  • Arca-Suárez, Jorge
[Abstract] We aimed to characterize OXA-1054, a novel carbapenem-hydrolyzing class D β-lactamase (CHDL) detected in a multidrug-resistant Pseudomonas aeruginosa clinical isolate. Antimicrobial susceptibility was determined by broth microdilution, and carbapenemase activity was confirmed by hydrolysis assays. Whole-genome sequencing via Illumina and PacBio platforms enabled comprehensive analysis of the resistome and plasmid architecture. The blaOXA-1054 gene was cloned in parallel with blaOXA-48 and blaOXA-198 into the pUCP24 plasmid. β-Lactamases were produced in P. aeruginosa PAO1 for comparative evaluation of the phenotypic impact of each. OXA-48, OXA-198, and OXA-1054 β-lactamases were purified and further subjected to steady-state kinetic analysis, and 50% inhibitory activity of β-lactamase inhibitors was determined. The clinical P. aeruginosa isolate ARGA00461 showed resistance to carbapenems and most β-lactam/β-lactamase inhibitor combinations and tested positive in carbapenem hydrolysis assays. Genomic analysis revealed that the P. aeruginosa isolate ARGA00461 carried a gene coding for a previously uncharacterized CHDL, designated OXA-1054, which is closely related to the OXA-372 enzyme of environmental origin. The blaOXA-1054 gene was located in a small (≈5 kbp) non-conjugative plasmid coexisting with a conjugative IncP plasmid, which likely facilitated its mobilization. Production of OXA-1054 in P. aeruginosa PAO1 conferred a broader spectrum of β-lactam resistance than other CHDLs. Enzyme kinetics confirmed carbapenem hydrolysis with catalytic efficiency comparable to OXA-48 and revealed higher affinity for cefepime compared to OXA-48 and OXA-198. Among the inhibitors tested, only avibactam demonstrated relevant inhibitory activity. OXA-1054 mediates broad-spectrum β-lactam resistance in P. aeruginosa, including carbapenems and β-lactam/β-lactamase inhibitor combinations., This study was supported by Instituto de Salud Carlos III (ISCIII) through projects PI21/00704, PI22/01212, PI24/00010, PI24/00920, and PI25/00116 and co-funded by the European Union. The research was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC, CB21/13/00055 and CB21/13/00099). Funding was also provided by Axencia Galega de Innovación (GAIN), Consellería de Innovación and Consellería de Economía, Emprego e Industria, Xunta de Galicia (IN607D 2021/12 to A.B., IN607A 2024/09 to G.B., and IN607D 2024/08 to J.A.-S.). L.G.-P. was financially supported by the ISCIII PFIS program (FI23/00074). G.P.-R. was supported by PI22/01212 and GAIN-Xunta de Galicia (IN606A 2025/020). L.S.-P. was financially supported by GAIN-Xunta de Galicia (IN606A 2024/022). M.A.G.-F. was financially supported by the ISCIII PFIS program (FI22/00039). S.R.-P. was financially supported by the ISCIII Río Hortega program (CM23/00104). T.B.-M. was financially supported by the ISCIII Juan Rodés program (JR25/00031). J.A.-S. was financially supported by the ISCIII Juan Rodés program (JR21/00026).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Contribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility in Pseudomonas aeruginosa

  • González-Pinto, Lucía
  • Gomis-Font, María Antonia
  • Pérez-Rodríguez, Gloria
  • Blanco Martín, Tania
  • Rodríguez-Pallares, Salud
  • Sánchez-Peña, Lucía
  • Beceiro Casas, Alejandro
  • Bou, Germán
  • Jeannot, Katy
  • Oliver, Antonio
  • Arca-Suárez, Jorge
[Abstract] Cefiderocol/xeruborbactam is a novel β-lactam/β-lactamase inhibitor combination in which the siderophore-cephalosporin cefiderocol is paired with xeruborbactam, a broad-spectrum inhibitor that targets class A to D β-lactamases. We evaluated the contribution of Pseudomonas aeruginosa resistance mechanisms to cefiderocol/xeruborbactam susceptibility. A panel of 61 P. aeruginosa PAO1 derivatives was tested, including 20 knockout mutants representing key chromosomal resistance mechanisms (e.g., ampC overexpression, efflux upregulation, porin loss, iron uptake deficiency) and 41 transformants producing major circulating β-lactamases. Xeruborbactam was assessed in combination with cefiderocol and cefepime at 4 and 8 mg/L and compared with taniborbactam. Additionally, 99 cefiderocol-resistant clinical P. aeruginosa isolates were evaluated. Cefiderocol/xeruborbactam retained activity against most P. aeruginosa mutants with chromosomally encoded resistance mechanisms. However, the P. aeruginosa piuC-defective mutant yielded increased cefiderocol minimum inhibitory concentrations (MIC = 2 mg/L), which could not be restored by xeruborbactam. Xeruborbactam significantly increased the activity of cefiderocol against the majority of P. aeruginosa PAO1 transformants, including those producing PER-1, SHV-12, KPC Ω-loop mutants, or NDM variants. Cefiderocol/xeruborbactam was active against IMP-type MBLs (which only weakly hydrolyze cefiderocol), including xeruborbactam-resistant enzymes. Relative to taniborbactam, xeruborbactam-based combinations showed similar activity against P. aeruginosa PAO1 transformants, but with slightly higher MIC values when tested against metallo-β-lactamase producers. This MIC increase in xeruborbactam-based combinations was partly because of the constitutive MexAB-OprM efflux in the P. aeruginosa background, as confirmed with P. aeruginosa PAO1 efflux mutants. Importantly, xeruborbactam restored susceptibility in 78% of 99 cefiderocol-resistant P. aeruginosa strains, reducing the MIC90 from 64 to 4 mg/L. Cefiderocol/xeruborbactam shows promising activity against P. aeruginosa., This study was supported by the Instituto de Salud Carlos III (ISCIII), through the projects PI20/01212, PI21/00704, PI22/01212, PI23/00851, PI24/00010, and PI24/00920, and co-funded by the European Union. The research was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC, CB21/13/00055, and CB21/13/00099). Funding was also provided by Axencia Galega de Innovación (GAIN), Consellería de Innovación and Consellería de Economía, Emprego e Industria, Xunta de Galicia (IN607D 2021/12 to A.B., IN607A 2024/09 to G.B., and IN607D 2024/008 to J.A.-S.). L.G.-P. was financially supported by the ISCIII PFIS program (FI23/00074). M.A.G.-F. was financially supported by the ISCIII PFIS program (FI22/00039). G.P.-R. was supported by PI22/01212. T.B.-M. was financially supported by the ISCIII Río Hortega program (CM23/00095). S.R.-P. was financially supported by the ISCIII Río Hortega program (CM23/00104). L.S.-P. was financially supported by GAIN-Xunta de Galicia (IN606A 2024/022). J.A.-S. was financially supported by the ISCIII Juan Rodés program (JR21/00026). The funders had no role in the study design, data collection and interpretation, or the decision to submit the work for publication.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Antibacterial activity of enmetazobactam against Acinetobacter spp.: a molecular dissection of mechanism of action and resistance determinants

  • Báez-Barroso, Gabriela Alejandra
  • Rodríguez-Coello, Arianna
  • Vázquez-Ucha, Juan Carlos
  • López-Argüello, Silvia
  • Outeda-García, Michelle
  • González-Pinto, Lucía
  • García-Pose, Andrea
  • Guijarro-Sánchez, Paula
  • Alonso-García, Isaac
  • Lence, Emilio
  • González-Bello, Concepción
  • Oliver, Antonio
  • Arca-Suárez, Jorge
  • Moya, Bartolomé
  • Bou, Germán
  • Beceiro Casas, Alejandro
[Abstract] The persistence of multidrug-resistant Acinetobacter baumannii remains a clinical challenge. Cefepime/enmetazobactam is a novel combination with demonstrated activity against extended-spectrum β-lactamase-producing Enterobacterales, but its activity against Acinetobacter has not yet been thoroughly explored. We aimed to assess its activity against Acinetobacter spp., including multidrug-resistant strains producing carbapenem-hydrolyzing class D β-lactamases (CHDLs). We analyzed 208 clinical isolates of Acinetobacter spp., including 67 carbapenem-resistant Acinetobacter baumannii (CRAB). Antibiotic susceptibility testing was conducted with cefepime, sulbactam, and imipenem, alone and in combination with enmetazobactam; the latter was also tested individually. Additionally, MICs of enmetazobactam/durlobactam and sulbactam/durlobactam were determined for CRAB and CHDL-producing A. baumannii ATCC 17978 transformants. PBP binding assays (IC₅₀), molecular docking, simulation studies with the enmetazobactam/OXA-23 adduct, hydrolysis kinetics (kcat, Km), and OXA-23 inhibition assays (IC₅₀, koff, t₁/₂) were performed to elucidate the mechanism of enmetazobactam and detect reduced susceptibility. Enmetazobactam showed high intrinsic activity against Acinetobacter spp., displaying reduced MICs against carbapenem-susceptible isolates. MIC50/90 of the enmetazobactam/durlobactam combination was 2/2 mg/L for CHDL-producing A. baumannii. Enmetazobactam exhibited bactericidal activity comparable to sulbactam. Binding assays revealed that the antimicrobial activity is driven by selective affinity for PBP2 (IC₅₀ 3.6 mg/L) and PBP3 (IC₅₀ 4.2 mg/L). OXA-23 readily inactivated enmetazobactam, confirming the major role of CHDLs in resistance to enmetazobactam, via substrate-assisted de-acylation. This study evidences the potent antimicrobial activity of enmetazobactam against A. baumannii via inhibition of PBP2 and PBP3. Its combination with new OXA-type inhibitors (e.g., durlobactam) represents a potential therapeutic alternative for multidrug-resistant A. baumannii., This research was supported by Projects PI20/01212 and PI23/00851 awarded to A.B., Project PI21/00704 awarded to G.B., and Project PI22/01212 awarded to J.A.-S., all funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. C.G.-B. acknowledges the financial support provided by the Spanish State Agency of Research (PID2022-136963OB-I00/AEI/10.13039/501100011033), the Axencia Galega de Innovación (GAIN; ED431C 2025/05 and Centro Singular de Investigación de Galicia accreditation 2024-2027 [ED431G 2023/03]), and the European Regional Development Fund. The research was also supported by CIBER-Consorcio Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (CB21/13/00055), Ministerio de Ciencia e Innovación and Unión Europea-NextGenerationEU and by project IN607D 2021/12 awarded to A.B., IN607A 2020/05 to G.B., and IN607D 2024/008 to J.A.-S. (GAIN-Agencia Gallega de Innovación. Consellería de Economía, Emprego e Industria). B.M. was funded by project CNS2024-154597 under the 2024 Research Consolidation Program, funded by the Spanish State Research Agency (Agencia Estatal de Investigación, AEI) through the 2024 call of the State ProgrammeProgram for the Promotion of Talent and also was financially supported within the framework of the State Plan for Scientific, Technical and Innovation Research 2024-2027. The authors thank the Fundación Pública Galega de Investigación Biomédica INIBIC (FINIBIC) for the financial support provided for the open access publication of this article. J.A.-S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026), J.C.V.-U. was financially supported by IN606B-2022/009 (Xunta de Galicia), P.G.-S. was financially supported by IN606A 2021/021 Grant (Xunta de Galicia). M.O.-G. was financially supported by IN606A 2023/023. I.A.-G. was financially supported by the Juan Rodés (ISCIII, JR23/00036). G.-A.B.-B. was financially supported by IN606A-2024/033. L.G.-P. was financially supported by the PFIS program (FI23/00074).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

In vivo evolution of resistance to novel β-lactam/β-lactamase inhibitor combinations through overproduction of the horizontally acquired extended-spectrum AmpC β-lactamase FOX-14 and porin disruption in Serratia marcescens

  • Rodríguez-Pallares, Salud
  • González-Pinto, Lucía
  • Tarriño-León, María
  • Aja-Macaya, Pablo
  • Sánchez-Peña, Lucía
  • Moscoso, Miriam
  • Pérez-Rodríguez, Gloria
  • Blanco Martín, Tania
  • Beceiro Casas, Alejandro
  • Bou, Germán
  • Arca-Suárez, Jorge
[Abstract] We investigated the genetic and biochemical determinants that reduce the activity of several β-lactam/β-lactamase inhibitor combinations against Serratia marcescens clinical isolates after carbapenem exposure. We analyzed paired clinical S. marcescens isolates recovered before and after treatment of a prolonged infection with ertapenem. We tested the susceptibility of the isolates to ceftazidime/avibactam, aztreonam/avibactam, imipenem/relebactam and meropenem/vaborbactam. Mechanisms of resistance were investigated using whole-genome sequencing and RNA expression analysis. The blaFOX-14 gene was cloned into Escherichia coli, to assess the phenotype in wild-type and low-permeability backgrounds. FOX-14 was purified to determine steady-state kinetics and avibactam IC50. The baseline isolate was susceptible to ceftazidime/avibactam, aztreonam/avibactam, imipenem/relebactam and meropenem/vaborbactam, whereas the post-therapy isolate displayed high-level resistance. The post-therapy isolate harboured a premature stop in ompF, loss of an additional putative porin, and overexpressed of blaFOX-14 due to triplication of the blaFOX-14 surrounding region. Cloning of blaFOX-14 conferred an extended-spectrum AmpC phenotype in E. coli, which was further accentuated under reduced permeability. Complementation of the post-therapy resistant clinical isolate with functional OmpF restored susceptibility to new β-lactam/β-lactamase inhibitor combinations. Purified FOX-14 displayed marked cephalosporinase activity against ceftazidime and cefepime, with low Km values, while negligible turnover for aztreonam and ertapenem and a low avibactam IC50. In S. marcescens, in vivo resistance in clinical isolates emerged from FOX-14 overproduction combined with reduced outer-membrane permeability, predominantly due to OmpF disruption. These findings elucidate resistance to newer β-lactam/β-lactamase inhibitor combinations and warrant close monitoring of antimicrobial activity during carbapenem-based therapy for S. marcescens infections., This work was supported by the Instituto de Salud Carlos III (ISCIII projects: PI24/00920, PI23/00851, PI22/01212, PI21/00704 and PI20/01212) and co-funded by the European Union. The research was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC; CB21/13/00055), integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016, and funded by the ISCIII-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe.” The study was also funded by Axencia Galega de Innovacion (GAIN), Conselleria de Innovacion, Conselleria de Emprego e Industria through “Proxectos de excelencia” (IN607D 2021/12 to A.B. and IN607D 2024/008 to J.A.-S.), and ‘’Axudas para a consolidación de grupos de investigación que pola súa produción científica e a súa actividade de I + D constitúan unha referencia no Sistema galego de I + D + I’’ (IN607A 2024/09 to G.B.). S.R.-P. was financially supported by the Río Hortega Program (ISCIII, CM23/00104). L.G.-P. was financially supported by the PFIS Program (ISCIII, FI23/00074). L.S.-P. was financially supported by Fundación Publica Galega de investigación Biomédica (INIBIC) and Xunta de Galicia (IN606A 2024/022). M.-M. was financially supported by CIBERINFEC. G.P.-R. was financially supported by the ISCIII Project PI22/01212. T.B.-M. was financially supported by the Río Hortega Program (ISCIII, CM23/00095). J.A.-S. was financially supported by the Juan Rodés Program (ISCIII, JR21/00026).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

In vitro susceptibility to imipenem/relebactam and comparators in a multicentre collection of mycobacterium abscessus complex isolates

  • Seoane-Estévez, Alejandro
  • Aja-Macaya, Pablo
  • García-Pose, Andrea
  • López-Roa, Paula
  • Ruedas-López, Alba
  • González-Galán, Verónica
  • Esteban, Jaime
  • Arca-Suárez, Jorge
  • Pampín, Martín
  • Beceiro Casas, Alejandro
  • Oviaño, Marina
  • Bou, Germán
[Abstract] Background and Objectives: Infections caused by non-tuberculous mycobacteria (NTM), including Mycobacterium abscessus complex (MABc), are increasing globally and are notoriously difficult to treat due to the intrinsic resistance of these bacteria to many common antibiotics. The aims of this study were to demonstrate the in vitro activity of imipenem/relebactam against MABc clinical isolates and to determine any in vitro synergism between imipenem/relebactam and other antimicrobials. Methods: A nationwide collection of 175 MABc clinical respiratory isolates obtained from 24 hospitals in Spain (August 2022–April 2023) was studied. Fifteen different antimicrobial agents were comprised, including imipenem/relebactam. MICs were determined according to CLSI criteria, and the synergism studies were performed with the selected clinical isolates. Results: Of the 175 isolates obtained, 110 were identified as M. abscessus subsp. abscessus (62.9%), 51 as M. abscessus subsp. massiliense (29.1%), and 14 as M. abscessus subsp. bolleti (8%). The antibiotics yielding the highest susceptibility rates were tigecycline, eravacycline, and omadacycline (100%); followed by imipenem/relebactam and clofazimine (97.6%); and finally amikacin (94.6%). Only four isolates were resistant to imipenem/relebactam, three of which were further characterized by WGS, revealing MABc mutations in BlaMab as well as D,D- and L,D-transpeptidades and mspA porin, which may play an important role in reduced susceptibility to imipenem/relebactam, even though none were previously described or associated with resistance to β-lactams. Conclusions: Our data demonstrate that relebactam improved the anti-MABc activity of imipenem, representing a β-lactam for the treatment of MABc infections. Furthermore, imipenem/relebactam demonstrated in vitro synergism with other anti-MABc treatments, thus supporting its use as part of dual regimens., This research was supported by the Instituto de Salud Carlos III (ISCIII, projects PI22/01212 to J.A.S., PI20/00686 to MO and PI21/00704 to GB) and co-funded by the European Union. The research was also supported by Merck Sharp & Dohme (MSD) through the Investigator Initiated Studies Program. The study was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC, CB21/13/00055) and by the Axencia Galega de Innovación (GAIN), Consellería de Innovación, Consellería de Economía, Emprego e Industria (IN607A to G.B.). The study was also funded by the Axencia Galega de Innovación (GAIN), Consellería de Innovación, Consellería de Emprego e Industria trough “Proxectos de excelencia” IN607D2021/12 to A.B and IN607D2024/008 to J.A.S. A.S.E. was financially supported by the Rio Hortega program (ISCIII, CM21/00230) and J.A.S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026). The Fundación Pública Galega de Investigación Biomédica INIBIC has paid the charges for the open access of the manuscript.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Comparative activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against recombinant β-lactamase-producing Escherichia coli and contemporary WGS-characterized strains of carbapenemase-producing Enterobacterales

  • Sánchez-Peña, Lucía
  • Rodríguez-Pallares, Salud
  • Blanco Martín, Tania
  • Pérez-Rodríguez, Gloria
  • Aja-Macaya, Pablo
  • González-Pinto, Lucía
  • López-Hernández, Inmaculada
  • Aracil, Belén
  • Beceiro Casas, Alejandro
  • Bou, Germán
  • Arca-Suárez, Jorge
Comparative study, [Abstract] We evaluated the activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against isogenic Escherichia coli and clinical Enterobacterales isolates producing broad-spectrum β-lactamases. Avibactam and ledaborbactam enhanced ceftibuten activity against transformants producing serine-β-lactamases. Ceftibuten/xeruborbactam was also active against VIM and some IMP producers. All combinations were active against OXA-48- and KPC-producing clinical isolates. Ceftibuten/xeruborbactam also retained activity against VIM-producing clinical strains. Susceptibility rates for MBL producers varied, depending on the CLSI or EUCAST breakpoints applied., This study was supported by the Instituto de Salud Carlos III (ISCIII) through projects PI21/00704, PI22/01212, PI23/00851, PI24/00920, and PI25/00116 co-funded by the European Union. The research was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CB21/13/00055). Funding was also provided by Axencia Galega de Innovación (GAIN), Consellería de Innovación, Consellería de Economía, Emprego e Industria, and Xunta de Galicia (IN607D 2021/12 to A.B., IN607A 2024/09 to G.B., and IN607D 2024/08 to J.A.-S.). L.S.-P. was financially supported by GAIN-Xunta de Galicia (IN606A 2024/022). S.R.-P. was financially supported by the ISCIII Río Hortega program (CM23/00104). T.B.-M. was financially supported by the ISCIII Río Hortega program (CM23/00095). G.P.-R. was supported by PI22/01212 and GAIN-Xunta de Galicia (IN606A 2025/020). L.G.-P. was financially supported by the ISCIII PFIS program (FI23/00074). J.A.-S. was financially supported by the ISCIII Juan Rodés program (JR21/00026).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Disarming carbapenemase-producing Acinetobacter baumannii: high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310)

  • Rodríguez-Pallares, Salud
  • Outeda-García, Michelle
  • Lence, Emilio
  • Rodríguez-Coello, Arianna
  • González-Pinto, Lucía
  • Guijarro-Sánchez, Paula
  • Báez-Barroso, Gabriela Alejandra
  • Blanco Martín, Tania
  • Vázquez-Ucha, Juan Carlos
  • Llanos, Agustina
  • Sannio, Filomena
  • Docquier, Jean-Denis
  • Hawser, Stephen
  • Zalacain, Magdalena
  • Lemonnier, Marc
  • González-Bello, Concepción
  • Bou, Germán
  • Beceiro Casas, Alejandro
  • Arca-Suárez, Jorge
[Abstract] Carbapenem-resistant Acinetobacter baumannii (CRAB) represents an urgent global health threat, with resistance primarily driven by carbapenem-hydrolyzing class D β-lactamases (CHDLs) such as OXA-23. Therapeutic options remain limited due to the scarcity of effective β-lactam/β-lactamase inhibitor combinations. Pilabactam (formerly ANT3310) is a novel diazabicyclooctane (DBO) β-lactamase inhibitor featuring a fluorine substituent that extends its activity spectrum, relative to approved DBOs like avibactam and relebactam, to include CHDLs. Pilabactam is currently in phase I clinical trials in combination with meropenem, and its activity and mechanism against CRAB remain incompletely defined. Using engineered A. baumannii strains producing individual β-lactamases, we show that pilabactam restores meropenem activity against serine β-lactamase producers, including difficult-to-inhibit CHDLs. This was corroborated in 68 whole-genome-sequenced meropenem-resistant clinical isolates, yielding MIC₅₀ and MIC₉₀ values for meropenem/pilabactam of 1 and 2 mg/L, respectively. Frequency of resistance studies in representative CHDL producers demonstrated suppression of resistance selection at 4× MIC. Kinetic analyses revealed that pilabactam inhibits OXA-23 via a two-step tight binding mechanism, with slightly higher inactivation rates (1.7 × 10⁴ M⁻¹s⁻¹) than that of durlobactam (3.5 × 10³ M⁻¹s⁻¹). Pilabactam also yielded a low dissociation constant (Kd ≈ 4 nM) and slow off-rate, indicating durable inhibition. Molecular dynamics simulations revealed the critical role of the fluorine substituent in forming stabilizing hydrogen-bonding and CH-F interactions within the tunnel-like OXA-23 active site. These findings identify pilabactam as a potent novel DBO supporting its development with meropenem for treating CRAB infections., This research was supported by Antabio through a service agreement with Fundación Publica Galega de Investigación Biomédica INIBIC. The study was supported by the Instituto de Salud Carlos III (ISCIII projects PI23/00851, PI22/01212, PI21/00704, and PI20/01212) and co-funded by the European Union. The research was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC; CB21/13/00055), integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016, and funded by the ISCIII-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe.” The study was also funded by Axencia Galega de Innovacion (GAIN), Conselleria de Innovacion, Conselleria de Emprego e Industria through “Proxectos de excelencia” (IN607D 2021/12 to A.B. and IN607D 2024/08 to J.A.-S.), and ‘’Axudas para a consolidación de grupos de investigación que pola súa produción científica e a súa actividade de I+D constitúan unha referencia no Sistema galego de I+D+I’’ (IN607A 2024/09 to G.B.). The study was also funded by the Spanish State Agency of Research (PID2022-136963OB-I00/AEI/10.13039/501100011033, C.G.-B.), the Xunta de Galicia [ED431C 2025/05 and Centro singular de investigación de Galicia accreditation 2023–2027 (ED431G 2023/03), C.G.-B.], and the European Regional Development Fund (ERDF). S.R.-P. was financially supported by the Río Hortega Program (ISCIII, CM23/00104). M.O.-G. was financially supported by IN606A 2023/023. A.R.-C. was supported by a predoctoral fellowship from the Instituto de Salud Carlos III (FI24/00178). L.G.-P. was financially supported by a predoctoral fellowship from the Instituto de Salud Carlos III (FI23/00074). G.A.B.-B. was financially supported by IN606A-2024/033 (Xunta de Galicia). T.B.-M. was financially supported by the Río Hortega Program (ISCIII, CM23/00095). J.C.V.-U. was financially supported by IN606B-2022/009 (Xunta de Galicia). J.A.-S. was financially supported by the Juan Rodés Program (ISCIII, JR21/00026). J.-D.D. was supported in part by the Italian Ministry of University and Research and the European Union (“Unione Europea—Next Generation EU, Missione 4 Componente 2 Inv. 1.5 CUP_B63C22001400007) in the frame of the PNRR PE-13 (“Piano Nazionale di Ripresa e Resilienza, Partenariato Esteso 13, Malattie infettive emergenti”) INF-ACT project (One Health Basic and Translational Research Actions addressing Unmet Needs on Emerging Infectious Diseases). This work was also supported by the Fundación Pública Galega de Investigación Biomédica INIBIC, which provided financial support for the final publication of the article.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations

  • Sánchez-Peña, Lucía
  • Rodríguez-Pallares, Salud
  • Aja-Macaya, Pablo
  • Blanco Martín, Tania
  • González-Pinto, Lucía
  • Pérez-Rodríguez, Gloria
  • Le Terrier, Christophe
  • Portillo-Calderón, Inés
  • Recacha, Esther
  • Riazzo, Cristina
  • Vázquez-Ucha, Juan Carlos
  • Beceiro Casas, Alejandro
  • Aracil, Belén
  • Oteo, Jesús
  • Martínez-Martínez, Luis
  • Poirel, Laurent
  • Bou, Germán
  • Arca-Suárez, Jorge
[Abstract] Xeruborbactam is a broad-spectrum boronate-type β-lactamase inhibitor. We aimed to evaluate its activity in combination with meropenem and compare it with other β-lactam/β-lactamase inhibitor combinations against Enterobacterales. The following isolates were screened: (i) an isogenic collection of 94 Escherichia coli isolates producing β-lactamases under wild-type and low-permeability conditions, (ii) 300 genetically diverse clinical Enterobacterales isolates producing the three main carbapenemase types (KPC-like, OXA-48-like, and metallo-β-lactamases), and (iii) two collections of isolates producing mechanisms of resistance to β-lactam/β-lactamase inhibitor combinations, such as KPC variants or PBP3 insertions combined with metallo-β-lactamases (MBLs). The MICs of meropenem, meropenem/xeruborbactam, meropenem/vaborbactam, imipenem, imipenem/relebactam, cefepime, cefepime/taniborbactam, ceftazidime, ceftazidime/avibactam, aztreonam, and aztreonam/avibactam were determined by reference broth microdilution and interpreted following the European Committee on Antimicrobial Susceptibility Testing guidelines, using the breakpoint of the β-lactam alone for not yet approved combinations. Resistance mechanisms of all clinical isolates were analyzed by whole genome sequencing. Meropenem/xeruborbactam had the broadest spectrum against the isogenic collection, although higher MICs were noted for transformants producing IMP-23, SPM-1, and NDM enzymes (these latter only when produced under low-permeability conditions). Meropenem/xeruborbactam displayed the most potent activity against the collection of 300 clinical strains (MIC50/90 ≤0.06/≤0.06 mg/L). Xeruborbactam restored meropenem activity against the strains carrying resistance mechanisms to β-lactam/β-lactamase inhibitor combinations, including strains producing KPC variants or MBLs in combination with additional chromosomal alterations (MIC range: ≤0.06-0.25 and ≤0.06-4 mg/L, respectively). Our findings highlight the potential of xeruborbactam in combination with meropenem as a promising treatment against carbapenemase-producing Enterobacterales, including strains with emerging resistance to other β-lactam/β-lactamase inhibitor combinations., Information & Contributors Metrics & Citations References Figures Tables Share ABSTRACT Xeruborbactam is a broad-spectrum boronate-type β-lactamase inhibitor. We aimed to evaluate its activity in combination with meropenem and compare it with other β-lactam/β-lactamase inhibitor combinations against Enterobacterales. The following isolates were screened: (i) an isogenic collection of 94 Escherichia coli isolates producing β-lactamases under wild-type and low-permeability conditions, (ii) 300 genetically diverse clinical Enterobacterales isolates producing the three main carbapenemase types (KPC-like, OXA-48-like, and metallo-β-lactamases), and (iii) two collections of isolates producing mechanisms of resistance to β-lactam/β-lactamase inhibitor combinations, such as KPC variants or PBP3 insertions combined with metallo-β-lactamases (MBLs). The MICs of meropenem, meropenem/xeruborbactam, meropenem/vaborbactam, imipenem, imipenem/relebactam, cefepime, cefepime/taniborbactam, ceftazidime, ceftazidime/avibactam, aztreonam, and aztreonam/avibactam were determined by reference broth microdilution and interpreted following the European Committee on Antimicrobial Susceptibility Testing guidelines, using the breakpoint of the β-lactam alone for not yet approved combinations. Resistance mechanisms of all clinical isolates were analyzed by whole genome sequencing. Meropenem/xeruborbactam had the broadest spectrum against the isogenic collection, although higher MICs were noted for transformants producing IMP-23, SPM-1, and NDM enzymes (these latter only when produced under low-permeability conditions). Meropenem/xeruborbactam displayed the most potent activity against the collection of 300 clinical strains (MIC50/90 ≤0.06/≤0.06 mg/L). Xeruborbactam restored meropenem activity against the strains carrying resistance mechanisms to β-lactam/β-lactamase inhibitor combinations, including strains producing KPC variants or MBLs in combination with additional chromosomal alterations (MIC range: ≤0.06–0.25 and ≤0.06–4 mg/L, respectively). Our findings highlight the potential of xeruborbactam in combination with meropenem as a promising treatment against carbapenemase-producing Enterobacterales, including strains with emerging resistance to other β-lactam/β-lactamase inhibitor combinations. INTRODUCTION Infections caused by carbapenemase-producing Enterobacterales (CPE), classified as “critical priority pathogens” by the World Health Organization (WHO), pose an important healthcare threat (1). This is due to the very limited repertoire of active antibiotics available for combating infections caused by these pathogens, as carbapenemases may exhibit a wide spectrum of activity against all β-lactams, commonly resulting in the so-called difficult-to-treat phenotypes (2). This complex clinical scenario is further exacerbated by the growing prevalence of CPE in all geographical regions and particularly producers of metallo-β-lactamases (MBLs), such as NDM, VIM, and IMP-type enzymes, which are recalcitrant to most clinically available newly developed β-lactam/β-lactamase inhibitor combinations (3). Thanks to intense drug discovery efforts in the last few decades, we are now witnessing a new era of β-lactam/β-lactamase inhibitor combinations with potent activity against multidrug-resistant Gram-negative microorganisms, including CPE (4). Most combinations usually rely on the partnership between broad-spectrum β-lactam antibiotics (e.g., cephalosporins and carbapenems) and two main classes of new β-lactamase inhibitors: (i) 1,6-diazabicyclo[3,2,1]octane (DBO) analogues (e.g., avibactam and relebactam) and (ii) cyclic boronates (e.g., vaborbactam). Current clinically available options include the carbapenem/β-lactamase inhibitors imipenem/relebactam and meropenem/vaborbactam, which display potent activity against KPC-producing strains, and ceftazidime/avibactam, with this latter combination also covering OXA-48-producers (5). While these additions represent an advance regarding the management of CPE infections, the problem is still far from being resolved, as none of the combinations provide coverage against the growing number of MBL-producing strains, due to a lack of inhibitory potential of those inhibitors against MBLs. Moreover, the increased use of ceftazidime/avibactam worldwide has had an important impact on the evolution of KPC β-lactamases, which can become refractory to the combination through acquisition of amino acid replacements in catalytically important regions, the so-called KPC resistant variants (6). Other recently approved or late-stage combinations which may mitigate these therapeutic gaps to some extent include aztreonam/avibactam and cefepime/taniborbactam. Aztreonam/avibactam takes advantage of the inefficiency of MBLs to inactivate aztreonam and the high potency of avibactam against serine-type enzymes, thus covering all types of CPE (7). On the other hand, the appearance in the clinical setting of cefepime/taniborbactam, which has already been demonstrated (in the recently published CERTAIN trial) to be superior to meropenem, corresponds to the first combination including a β-lactamase inhibitor with ultrabroad spectrum of β-lactamase coverage, including MBLs (8). However, CPE represent a continuously moving target, and strains showing emerging resistance mechanisms to these combinations are already expanding. Most of these strains include multidrug-resistant Escherichia coli lineages (e.g., ST410 and ST167) which are often producing NDM enzymes but also exhibit insertions into their specific penicillin-binding protein 3 (PBP3) (9). These strains are commonly resistant to aztreonam/avibactam but also to all other clinically available or investigational β-lactam/β-lactamase inhibitors, including cefepime/taniborbactam. Thus, new agents active against these emerging threats are urgently needed (10). A novel ultrabroad-spectrum bicyclic boronate type inhibitor was recently discovered by rational modification of a benzoxaborinine scaffold: xeruborbactam (formerly QPX7728) (11). Xeruborbactam demonstrates a potent and ultrabroad spectrum of β-lactamase coverage, being able to inhibit class A, B, C, and D enzymes in the nanomolar range. Xeruborbactam also outperforms other inhibitors in acting against key enzymatic targets at the biochemical level, such as vaborbactam against KPC enzymes and avibactam against OXA-48-like variants (12). Moreover, xeruborbactam has proven potent biochemical activity and in vitro potency against MBLs, including IMP-like enzymes and NDM-9 variants, which are resistant to the inhibitory action of taniborbactam (13–15). Xeruborbactam is currently undergoing evaluation in clinical trials with different intravenous and orally available β-lactams. Its potency in previous microbiological studies has mainly been in combination with meropenem (16). Most of these studies provide data obtained on large collections of randomly selected clinical strains isolated in large surveillance studies (17). Thus, in order to obtain more information about its therapeutic potential against CPE and aid in its precise therapeutic positioning, we evaluated the activity of xeruborbactam against a large collection of isogenic E. coli strains with defined β-lactamase content, as well as against large collections of genetically unrelated and whole-genome sequencing (WGS)-characterized CPE strains, including collections of isolates being resistant to combinations such as ceftazidime/avibactam, aztreonam/avibactam, and cefepime/taniborbactam. RESULTS AND DISCUSSION Activity of meropenem/xeruborbactam against E. coli isogenic strains We first evaluated the antimicrobial activity of meropenem/xeruborbactam and comparator agents against an isogenic panel of E. coli strains producing single or double β-lactamases under wild-type and low-permeability conditions (Table 1). Meropenem/xeruborbactam demonstrated near-total activity (MIC range: ≤0.06–16 mg/L; 92/94 susceptible strains) against the collection of E. coli laboratory transformants, although some notable effects on its activity were noted in relation to the class of β-lactamase produced and the permeability status. This high potency is likely explained by the strong activity of xeruborbactam against all β-lactamases but could also be due to its previously observed intrinsic antibacterial activity against E. coli, where xeruborbactam alone has demonstrated MICs ranging from 2 to 32 mg/L (18). TABLE 1 TABLE 1 Antibiotic susceptibility data for newly developed β-lactam/β-lactamase inhibitor combinations against isogenic E. coli TG1 and HB4 transformants expressing the most relevant class A, B, C, and D β-lactamases and double carbapenemases found in Enterobacterales under wild-type and low-permeability conditions Strain Ambler class Main phenotype MIC (mg/L)a,b,c E. coli TG1 E. coli HB4 MEM (R > 8) M/X (R > 8) M/V (R > 8) I/R (R > 2) F/T (R > 4) CAZ (R > 4) C/A (R > 8) A/A (R > 4) MEM (R > 8) M/X (R > 8) M/V (R > 8) I/R (R > 2) F/T (R > 4) CAZ (R > 4) C/A (R > 8) A/A (R > 4) E. coli TG1 – Wild-type ≤0.06 ≤0.06 ≤0.06 0.125 ≤0.06 0.125 0.125 ≤0.06 – – – – – – – – E. coli HB4 – OmpF- and OmpC-deficient – – – – – – – – ≤0.06 ≤0.06 ≤0.06 0.125 0.5 1 0.5 0.125 GES-1 A ESBL ≤0.06 ≤0.06 ≤0.06 0.125 ≤0.06 4 0.125 ≤0.06 ≤0.06 ≤0.06 ≤0.06 0.125 0.5 16 1 0.125 GES-5 A Carbapenemase ≤0.06 ≤0.06 ≤0.06 0.125 ≤0.06 0.25 0.125 ≤0.06 2 ≤0.06 ≤0.06 0.125 0.5 2 0.5 0.125 GES-7 A ESBL ≤0.06 ≤0.06 ≤0.06 0.25 ≤0.06 32 0.25 ≤0.06 ≤0.06 ≤0.06 ≤0.06 0.125 0.5 >64 1 0.125 GES-20 A Carbapenemase ≤0.06 ≤0.06 ≤0.06 0.25 ≤0.06 0.25 0.125 ≤0.06 2 ≤0.06 ≤0.06 0.125 0.5 2 0.5 0.125 CTX-M-9 A ESBL ≤0.06 ≤0.06 ≤0.06 0.125 ≤0.06 0.5 0.125 ≤0.06 0.25 ≤0.06 ≤0.06 0.125 0.5 4 0.5 0.125 CTX-M-15 A ESBL ≤0.06 ≤0.06 ≤0.06 0.125 ≤0.06 32 0.125 ≤0.06 0.25 ≤0.06 ≤0.06 0.125 1 >64 1 0.125 SHV-12 A ESBL ≤0.06 ≤0.06 ≤0.06 0.125 ≤0.06 >64 0.25 0.125 0.25 ≤0.06 ≤0.06 0.125 1 >64 4 0.5 PER-1 A ESBL ≤0.06 ≤0.06 ≤0.06 0.125 ≤0.06 >64 2 2 ≤0.06 ≤0.06 ≤0.06 ≤0.06 1 >64 16 16 VEB-1 A ESBL ≤0.06 ≤0.06 ≤0.06 0.125 ≤0.06 >64 0.25 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 0.5 >64 2 1 VEB-25 A ESBL ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 >64 64 16 0.125 ≤0.06 ≤0.06 ≤0.06 1 >64 >64 64 BEL-1 A ESBL ≤0.06 ≤0.06 ≤0.06 0.125 ≤0.06 4 0.125 ≤0.06 0.125 ≤0.06 ≤0.06 ≤0.06 1 32 0.5 ≤0.06 SFO-1 A ESBL ≤0.06 ≤0.06 ≤0.06 ≤0.06 0.125 16 0.125 ≤0.06 0.25 ≤0.06 ≤0.06 ≤0.06 0.5 32 1 ≤0.06 KPC-2 A Carbapenemase 1 ≤0.06 ≤0.06 0.25 ≤0.06 16 0.25 0.125 >64 ≤0.06 0.125 0.5 1 >64 2 1 KPC-35 A ESBL ≤0.06 ≤0.06 ≤0.06 0.125 ≤0.06 >64 8 ≤0.06 0.5 ≤0.06 0.25 0.125 2 >64 32 0.25 KPC-3 A Carbapenemase 1 ≤0.06 ≤0.06 0.125 ≤0.06 32 0.25 ≤0.06 32 ≤0.06 ≤0.06 0.125 1 >64 4 0.125 KPC-31 A ESBL ≤0.06 ≤0.06 ≤0.06 0.125 ≤0.06 64 16 ≤0.06 0.25 ≤0.06 0.125 0.125 2 >64 64 0.25 VIM-1 B Carbapenemase 0.5 ≤0.06 0.5 2 1 >64 >64 ≤0.06 16 ≤0.06 16 2 8 >64 >64 0.125 VIM-2 B Carbapenemase ≤0.06 ≤0.06 ≤0.06 0.25 ≤0.06 1 1 ≤0.06 0.5 ≤0.06 0.5 0.25 0.5 8 8 0.125 VIM-4 B Carbapenemase 0.125 ≤0.06 0.125 0.125 ≤0.06 8 2 ≤0.06 4 ≤0.06 4 0.25 0.5 32 8 ≤0.06 VIM-20 B Carbapenemase ≤0.06 ≤0.06 ≤0.06 0.25 ≤0.06 >64 2 ≤0.06 2 ≤0.06 2 1 0.5 16 16 0.125 IMP-8 B Carbapenemase 2 ≤0.06 0.5 2 32 >64 >64 ≤0.06 16 0.25 8 8 >64 >64 >64 ≤0.06 IMP-13 B Carbapenemase ≤0.06 ≤0.06 ≤0.06 0.25 8 >64 >64 ≤0.06 2 ≤0.06 2 1 32 >64 >64 0.125 IMP-23 B Carbapenemase 0.5 0.5 0.5 0.125 8 >64 4 ≤0.06 64 16 64 2 >64 >64 >64 ≤0.06 IMP-94 B Carbapenemase ≤0.06 ≤0.06 ≤0.06 0.25 4 >64 >64 ≤0.06 1 ≤0.06 1 1 32 >64 >64 0.125 NDM-1 B Carbapenemase 2 ≤0.06 2 1 1 >64 >64 ≤0.06 64 4 64 16 16 >64 >64 0.25 NDM-5 B Carbapenemase 32 ≤0.06 32 32 8 >64 >64 ≤0.06 >64 1 >64 >64 >64 >64 >64 0.25 NDM-7 B Carbapenemase 16 ≤0.06 16 16 4 >64 >64 ≤0.06 >64 2 >64 >64 >64 >64 >64 0.25 NDM-23 B Carbapenemase 2 ≤0.06 2 2 1 >64 >64 ≤0.06 32 0.25 32 8 32 >64 >64 0.25 SPM-1 B Carbapenemase 0.5 0.125 0.25 0.125 0.125 >64 64 ≤0.06 32 16 32 0.25 2 >64 >64 ≤0.06 AmpC (K. aerogenes) C AmpC ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 64 0.25 0.125 4 ≤0.06 1 ≤0.06 1 >64 2 0.5 AmpC (E. cloacae) C AmpC ≤0.06 ≤0.06 ≤0.06 0.125 ≤0.06 32 0.125 0.125 0.5 ≤0.06 ≤0.06 ≤0.06 0.5 64 0.5 0.25 CMH-7 C AmpC ≤0.06 ≤0.06 ≤0.06 0.125 ≤0.06 32 0.125 ≤0.06 0.25 ≤0.06 ≤0.06 0.125 0.5 64 0.5 0.25 CMY-2 C AmpC ≤0.06 ≤0.06 ≤0.06 0.25 ≤0.06 >64 0.5 0.25 0.5 ≤0.06 ≤0.06 0.25 0.5 >64 2 1 DHA-1 C AmpC ≤0.06 ≤0.06 ≤0.06 0.125 ≤0.06 32 0.125 ≤0.06 0.25 ≤0.06 ≤0.06 0.125 0.5 >64 1 0.25 FOX-4 C AmpC ≤0.06 ≤0.06 ≤0.06 0.25 ≤0.06 >64 1 ≤0.06 0.25 ≤0.06 ≤0.06 0.125 0.5 >64 4 0.25 OXA-1 D Narrow-spectrum oxacillinase ≤0.06 ≤0.06 ≤0.06 ≤0.06 0.5 0.125 0.125 0.125 0.125 ≤0.06 0.125 ≤0.06 32 1 0.5 ≤0.06 OXA-2 D Narrow-spectrum oxacillinase ≤0.06 ≤0.06 ≤0.06 0.125 ≤0.06 2 ≤0.06 ≤0.06 1 ≤0.06 1 0.5 0.5 16 1 0.125 OXA-10 D Narrow-spectrum oxacillinase ≤0.06 ≤0.06 ≤0.06 0.125 ≤0.06 0.125 ≤0.06 0.125 2 ≤0.06 2 0.25 0.5 2 0.5 1 OXA-14 D ESBL ≤0.06 ≤0.06 ≤0.06 0.125 ≤0.06 32 4 0.125 0.5 ≤0.06 0.5 0.125 1 >64 64 1 OXA-15 D ESBL ≤0.06 ≤0.06 ≤0.06 0.125 ≤0.06 32 2 ≤0.06 0.125 ≤0.06 0.125 0.125 1 64 16 0.125 OXA-48 D Carbapenemase 0.5 ≤0.06 0.25 0.25 ≤0.06 0.25 ≤0.06 ≤0.06 8 ≤0.06 8 1 0.5 1 0.5 0.25 KPC-3 + VIM-1 A + B Double carbapenemase 1 ≤0.06 0.125 0.5 0.25 64 32 ≤0.06 32 ≤0.06 8 1 8 >64 >64 0.25 KPC-3 + IMP-94 A + B Double carbapenemase 1 ≤0.06 0.125 0.5 2 64 64 ≤0.06 32 ≤0.06 8 0.5 16 >64 >64 0.25 KPC-3 + OXA-48 A + D Double carbapenemase 1 ≤0.06 0.125 0.25 ≤0.25 16 ≤0.25 ≤0.06 16 ≤0.06 2 0.5 32 >64 0.5 0.25 NDM-1 + OXA-48 B + D Double carbapenemase 4 ≤0.06 4 8 8 >64 >64 ≤0.06 >64 2 64 4 32 >64 >64 0.25 OXA-48 + VIM-1 B + D Double carbapenemase 0.5 ≤0.06 0.25 0.5 0.25 >64 32 ≤0.06 8 ≤0.06 8 2 4 >64 >64 0.25 OXA-48 + IMP-94 B + D Double carbapenemase 0.25 ≤0.06 0.25 1 4 64 32 ≤0.06 16 ≤0.06 16 1 32 >64 >64 0.25 a MEM: meropenem; M/X: meropenem/xeruborbactam; M/V: meropenem/vaborbactam; I/R: imipenem/relebactam; F/T: cefepime/taniborbactam; CAZ: ceftazidime; C/A: ceftazidime/avibactam; A/A: aztreonam/avibactam. b EUCAST breakpoints indicated for Enterobacterales. Clinical breakpoints for combinations that have not yet been approved (meropenem/xeruborbactam and cefepime/taniborbactam) were interpreted using those of the β-lactam partner. Avibactam, relebactam, and taniborbactam were tested at a fixed concentration of 4 mg/L, while vaborbactam and xeruborbactam were tested at 8 mg/L. c –, not applicable. The E. coli TG1 transformants generally yielded meropenem/xeruborbactam MIC values ≤0.06 mg/L. Notably, this high activity was maintained against almost all MBL-producing strains, including those carrying NDMs, against which the addition of xeruborbactam potentiated the activity of meropenem at least 512-fold (from 32 to ≤0.06 mg/L). However, the highest MIC values were observed for the transformants producing SPM-1 (MIC = 0.125 mg/L) and IMP-23 (MIC = 0.5 mg/L). The SPM-1 MBL has been shown to resist the inhibitory activity of xeruborbactam in a recent study, along with other relatively rare MBLs such as SIM-1, PFM-1, and AIM-1. On the other hand, the IMP-23 enzyme also exhibits resistance to xeruborbactam. Interestingly, this variant contains a V67F amino acid substitution that affects a β-hairpin loop in the enzyme’s active site, a modification recently linked to xeruborbactam resistance by Le Terrier et al. (13), following genetic and biochemical analysis of IMP-10, a V67F variant of IMP-1. The IMP-23 enzyme is encoded in the genomes of Citrobacter freundii (GenBank accession number NG_049187.1) and Klebsiella pneumoniae (GenBank accession number CP097249.1) isolates from China and Taiwan, respectively, whereas the IMP-10 was found to be common in Asia (19). Altogether, these data highlight the need for close monitoring of xeruborbactam-resistant IMP variants and further mechanistic research with these enzymes to gain insights into the evolutionary potential of MBLs toward xeruborbactam resistance. Regarding the rest of the combinations, with the exception of aztreonam/avibactam, the MBL-producing strains (particularly those carrying NDM enzymes) yielded high MIC values for most of the other comparator combinations analyzed, including to some extent the novel combination with anti-MBL activity, cefepime/taniborbactam, as previously observed with recombinant E. coli isolates (20). In contrast, aztreonam/avibactam MICs were slightly elevated against transformants producing PER-1 and VEB-25 (MIC = 2 and 16 mg/L, respectively) and to a lesser extent CMY-2 (MIC = 0.25 mg/L), as previously described (21). Analysis of β-lactamase production in the porin-deficient E. coli HB4 host revealed the significant impact of low permeability on the interplay with these enzymes, as demonstrated by the large increase in MICs for most of the combinations tested. This effect was particularly noteworthy for meropenem and enabled a precise analysis of the inhibitory effect of xeruborbactam. Interestingly, xeruborbactam completely restored meropenem activity against most E. coli HB4 derivatives, reducing the MIC of meropenem to ≤0.06 mg/L, except for those transformants producing NDM enzymes (for which the MIC ranged from 0.25 to 4 mg/L), and the above-mentioned xeruborbactam-resistant variants SPM-1 (MIC = 16 mg/L) and IMP-23 (MIC = 16 mg/L). The reduced activity of meropenem/xeruborbactam against NDM-producing Enterobacterales with disrupted porins was noted in a previous study (22). The association between porin lesions and production of NDM enzymes also yielded very high MIC values for the cefepime/taniborbactam combination, a phenomenon previously observed in clinical isolates of NDM-producing K. pneumoniae, raising further concern about the spectrum of action of these enzymes, particularly when combined with additional mutational resistance mechanisms (5). Activity of meropenem/xeruborbactam against clinical CPE strains Detailed MIC values for all 300 clinical strains are shown in Tables S3 to S5. Among the 300 CPE isolates tested, the meropenem/xeruborbactam combination demonstrated exceptional activity, with MIC50 and MIC90 values ≤ 0.06 mg/L. All isolates were inhibited by meropenem/xeruborbactam at ≤4 mg/L, resulting in 100% susceptibility across the entire collection considering the breakpoint of meropenem alone (Table 2; Fig. 1). The addition of xeruborbactam reduced the meropenem MIC90 by more than 1,064-fold (from 64 to ≤0.06 mg/L). When comparing the activity of meropenem/xeruborbactam with that of other combinations active against both serine- and metallo-β-lactamases producers, such as aztreonam/avibactam and cefepime/taniborbactam, we found that the latter combinations retained activity against 99.3% and 92.7% of the collection, respectively, while the others did not exceed 90% activity in any case. This global overview emphasizes the robust potency of meropenem/xeruborbactam, which would effectively cover virtually all CPE currently circulating in Spain. TABLE 2 TABLE 2 In vitro antibiotic susceptibility activity data for meropenem/xeruborbactam and comparator agents against clinical CPE isolates with defined carbapenemase contentc Carbapenemase type Antimicrobial agent(s)a MIC (mg/L) MIC50 MIC90 Range % Susb % Resb ≤0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 >64 All (n = 300) MEM 6 (2.0%) 14 (4.7%) 44 (14.7%) 90 (30.0%) 137 (45.7%) 172 (57.3%) 198 (66.0%) 222 (74.0%) 248 (82.7%) 261 (87.0%) 278 (92.7%) 300 (100.0%) 2 64 ≤0.06–>64 74.0 26.0 M/X 270 (90.0%) 283 (94.3%) 292 (97.3%) 294 (98.0%) 295 (98.3%) 298 (99.3%) 300 (100.0%) ≤0.06 ≤0.06 ≤0.06–4 100.0 0.0 M/V 68 (22.7%) 80 (26.7%) 119 (39.7%) 178 (59.3%) 223 (74.3%) 243 (81.0%) 255 (85.0%) 267 (89.0%) 281 (93.7%) 290 (96.7%) 298 (99.3%) 300 (100.0%) 0.5 16 ≤0.06–>64 89.0 11.0 I/R 21 (7.0%) 63 (21.0%) 86 (28.7%) 143 (47.7%) 201 (67.0%) 247 (82.3%) 270 (90.0%) 281 (93.7%) 288 (96.0%) 295 (98.3%) 298 (99.3%) 300 (100.0%) 1 4 ≤0.06–>64 82.3 17.7 F/T 52 (17.3%) 73 (24.3%) 122 (40.7%) 163 (54.3%) 217 (72.3%) 253 (84.3%) 278 (92.7%) 288 (96.0%) 292 (97.3%) 292 (97.3%) 299 (99.7%) 300 (100.0%) 0.5 4 ≤0.06–>64 92.7 7.3 C/A 8 (2.7%) 24 (8.0%) 37 (12.3%) 77 (25.7%) 121 (40.3%) 155 (51.7%) 172 (57.3%) 187 (62.3%) 195 (65.0%) 201 (67.0%) 205 (68.3%) 300 (100.0%) 2 >64 ≤0.06–>64 62.3 37.7 A/A 101 (33.7%) 215 (71.7%) 263 (87.7%) 287 (95.7%) 292 (97.3%) 297 (99.0%) 298 (99.3%) 299 (99.7%) 300 (100.0%) 0.125 0.5 ≤0.06–16 99.3 0.7 OXA-48-like (n = 100) MEM 2 (2.0%) 6 (6.0%) 20 (20.0%) 43 (43.0%) 65 (65.0%) 74 (74.0%) 75 (75.0%) 78 (78.0%) 89 (89.0%) 94 (94.0%) 100 (100.0%) 1 32 ≤0.06–64 78.0 22.0 M/X 90 (90.0%) 97 (97.0%) 99 (99.0%) 100 (100.0%) ≤0.06 ≤0.06 ≤0.06–0.5 100.0 0.0 M/V 4 (4.0%) 7 (7.0%) 24 (24.0%) 47 (47.0%) 68 (68.0%) 74 (74.0%) 78 (78.0%) 80 (80.0%) 91 (91.0%) 94 (94.0%) 100 (100.0%) 1 16 ≤0.06–64 80.0 20.0 I/R 1 (1.0%) 4 (4.0%) 10 (10.0%) 34 (34.0%) 59 (59.0%) 81 (81.0%) 86 (86.0%) 90 (90.0%) 92 (92.0%) 97 (97.0%) 98 (98.0%) 100 (100.0%) 1 8 ≤0.06–>64 81.0 19.0 F/T 27 (27.0%) 33 (33.0%) 48 (48.0%) 55 (55.0%) 78 (78.0%) 88 (88.0%) 97 (97.0%) 99 (99.0%) 99 (99.0%) 100 (100.0%) 0.5 4 ≤0.06–32 97.0 3.0 C/A 7 (7.0%) 18 (18.0%) 28 (28.0%) 53 (53.0%) 77 (77.0%) 90 (90.0%) 97 (97.0%) 97 (97.0%) 98 (98.0%) 99 (99.0%) 99 (99.0%) 100 (100.0%) 0.5 2 ≤0.06–>64 97.0 3.0 A/A 42 (42.0%) 75 (75.0%) 92 (92.0%) 96 (96.0%) 97 (97.0%) 99 (99.0%) 99 (99.0%) 99 (99.0%) 100 (100.0%) 0.125 0.25 ≤0.06–16 99.0 1.0 KPC-like (n = 100) MEM 2 (2.0%) 3 (3.0%) 6 (6.0%) 8 (8.0%) 13 (13.0%) 32 (32.0%) 45 (45.0%) 55 (55.0%) 66 (66.0%) 70 (70.0%) 80 (80.0%) 100 (100.0%) 8 >64 ≤0.06–>64 55.0 45.0 M/X 95 (95.0%) 96 (96.0%) 99 (99.0%) 99 (99.0%) 99 (99.0%) 100 (100.0%) ≤0.06 ≤0.06 ≤0.06–2 100.0 0.0 M/V 61 (61.0%) 66 (66.0%) 75 (75.0%) 87 (87.0%) 96 (96.0%) 98 (98.0%) 98 (98.0%) 98 (98.0%) 98 (98.0%) 99 (99.0%) 100 (100.0%) ≤0.06 1 ≤0.06–64 98.0 2.0 I/R 20 (20.0%) 58 (58.0%) 72 (72.0%) 88 (88.0%) 98 (98.0%) 99 (99.0%) 100 (100.0%) 0.125 1 ≤0.06-4 99.0 1.0 F/T 23 (23.0%) 34 (34.0%) 47 (47.0%) 63 (63.0%) 77 (77.0%) 92 (92.0%) 99 (99.0%) 100 (100.0%) 0.5 2 ≤0.06–8 99.0 1.0 C/A 1 (1.0%) 6 (6.0%) 9 (9.0%) 24 (24.0%) 44 (44.0%) 65 (65.0%) 75 (75.0%) 89 (89.0%) 95 (95.0%) 98 (98.0%) 98 (98.0%) 100 (100.0%) 2 16 ≤0.06–>64 89.0 11.0 A/A 23 (23.0%) 75 (75.0%) 93 (93.0%) 99 (99.0%) 99 (99.0%) 100 (100.0%) 0.125 0.25 ≤0.06–2 100.0 0.0 MBL (n = 100) MEM 2 (2.0%) 5 (5.0%) 18 (18.0%) 39 (39.0%) 59 (59.0%) 66 (66.0%) 78 (78.0%) 89 (89.0%) 93 (93.0%) 97 (97.0%) 98 (98.0%) 100 (100.0%) 1 16 ≤0.06–>64 89.0 11.0 M/X 85 (85.0%) 90 (90.0%) 94 (94.4%) 95 (95.0%) 96 (96.0%) 98 (98.0%) 100 (100.0%) ≤0.06 0.125 ≤0.06–4 100.0 0.0 M/V 3 (3.0%) 7 (7.0%) 20 (20.0%) 44 (44.0%) 59 (59.0%) 71 (71.0%) 79 (79.0%) 89 (89.0%) 92 (92.0%) 97 (97.0%) 98 (98.0%) 100 (100.0%) 1 16 ≤0.06–>64 89.0 11.0 I/R 1 (1.0%) 4 (4.0%) 21 (21.0%) 44 (44.0%) 67 (67.0%) 84 (84.0%) 91 (91.0%) 96 (96.0%) 98 (98.0%) 100 (100.0%) 2 8 0.125–64 67.0 33.0 F/T 2 (2.0%) 6 (6.0%) 27 (27.0%) 45 (45.0%) 62 (62.0%) 73 (73.0%) 82 (82.0%) 89 (89.0%) 93 (93.0%) 97 (97.0%) 99 (99.0%) 100 (100.0%) 1 16 ≤0.06–>64 82.0 18.0 C/A 1 (1.0%) 2 (2.0%) 4 (4.0%) 8 (8.0%) 100 (100.0%) >64 >64 8–>64 1.0 99.0 A/A 36 (36.0%) 65 (65.0%) 78 (78.0%) 92 (92.0%) 96 (96.0%) 98 (98.0%) 99 (99.0%) 100 (100.0%) 0.125 0.5 ≤0.06–8 99.0 1.0 VIM (n = 63) MEM 2 (3.2%) 5 (7.9%) 17 (27.0%) 36 (57.1%) 52 (82.5%) 56 (88.9%) 57 (90.5%) 61 (96.8%) 61 (96.8%) 62 (98.4%) 62 (98.4%) 63 (100.0%) 0.5 4 ≤0.06–>64 96.8 3.2 M/X 57 (90.5%) 57 (90.5%) 60 (95.2%) 60 (95.2%) 61 (96.8%) 62 (98.4%) 63 (100.0%) ≤0.06 ≤0.06 ≤0.06–4 100.0 0.0 M/V 3 (4.8%) 7 (11.1%) 19 (30.2%) 40 (63.5%) 52 (82.5%) 57 (90.5%) 58 (92.1%) 61 (96.8%) 61 (96.8%) 62 (98.4%) 62 (98.4%) 63 (100.0%) 0.5 2 ≤0.06–>64 96.8 3.2 I/R 1 (1.6%) 4 (6.3%) 18 (28.6%) 38 (60.3%) 50 (79.4%) 58 (92.1%) 60 (95.2%) 61 (96.8%) 62 (98.4%) 63 (100.0%) 1 4 0.125–64 79.4 20.6 F/T 2 (3.2%) 5 (7.9%) 26 (41.3%) 37 (58.7%) 47 (74.6%) 55 (87.3%) 59 (93.7%) 60 (95.2%) 61 (96.8%) 61 (96.8%) 63 (100.0%) 0.5 4 ≤0.06–64 93.7 6.3 C/A 1 (1.6%) 2 (3.2%) 4 (6.3%) 8 (12.7%) 63 (100.0%) >64 >64 8–>64 1.6 98.4 A/A 21 (33.3%) 42 (66.7%) 51 (81.0%) 61 (96.8%) 62 (98.4%) 63 (100.0%) 0.125 0.5 ≤0.06–2 100.0 0.0 NDM (n = 32) MEM 3 (9.4%) 5 (15.6%) 16 (50.0%) 23 (71.9%) 27 (84.4%) 30 (93.8%) 31 (96.9%) 32 (100.0%) 4 32 1–>64 71.9 28.1 M/X 23 (71.9%) 28 (87.5%) 29 (90.6%) 30 (93.8%) 30 (93.8%) 31 (96.9%) 32 (100.0%) ≤0.06 0.25 ≤0.06-4 100.0 0.0 M/V 1 (3.1%) 3 (9.4%) 9 (28.1%) 16 (50.0%) 23 (71.9%) 26 (81.3%) 30 (93.8%) 31 (96.9%) 32 (100.0%) 4 32 0.5–>64 71.9 28.1 I/R 1 (3.1%) 2 (6.3%) 12 (37.5%) 21 (65.6%) 26 (81.3%) 30 (93.8%) 31 (96.9%) 32 (100.0%) 4 16 0.5–64 37.5 62.5 F/T 1 (3.1%) 1 (3.1%) 8 (25.0%) 15 (46.9%) 18 (56.3%) 23 (71.9%) 27 (84.4%) 29 (90.6%) 31 (96.9%) 31 (96.9%) 32 (100.0%) 2 16 0.125–>64 71.9 28.1 C/A 32 (100.0%) >64 >64 >64–>64 0.0 100.0 A/A 14 (43.8%) 20 (62.5%) 23 (71.9%) 27 (84.4%) 29 (90.6%) 30 (93.8%) 31 (96.9%) 32 (100.0%) 0.125 1 ≤0.06–8 96.9 3.1 a MEM: meropenem; M/X: meropenem/xeruborbactam; M/V: meropenem/vaborbactam; I/R: imipenem/relebactam; F/T: cefepime/taniborbactam; C/A: ceftazidime/avibactam; A/A: aztreonam/avibactam. b EUCAST breakpoints indicated for Enterobacterales. Clinical breakpoints for combinations that have not yet been approved (meropenem/xeruborbactam and cefepime/taniborbactam) were interpreted using those of the β-lactam partner. c Empty cells indicate the cumulative percentage of isolates already reaches 100% at lower MIC values for each combination. Fig 1 Line graphs present cumulative percent of Enterobacterales isolates versus MIC for antibiotic combinations across CPE, OXA-48, KPC, MBL, VIM, and NDM subgroups. MX consistently achieves highest activity, while CA performs poorest against MBL types. Fig 1 (A) Cumulative MIC values of all CPE isolates, (B) OXA-48-like-producing isolates, (C) KPC-producing isolates, (D) MBL-producing isolates. MBL-producing isolates are also divided into (E) VIM-producing isolates and (F) NDM-producing isolates. MEM: meropenem; M/X: meropenem/xeruborbactam; M/V: meropenem/vaborbactam; I/R: imipenem/relebactam; F/T: cefepime/taniborbactam; C/A: ceftazidime/avibactam; A/A: aztreonam/avibactam. Meropenem/xeruborbactam was the most active combination against OXA-48-like-producing Enterobacterales. For this subset of strains, the MIC50 and MIC90 values were ≤0.06 mg/L, with the MIC range significantly reduced compared to the whole collection. All strains within this subset were inhibited at ≤0.5 mg/L. The enhanced activity can be attributed to three factors: (i) the already relatively high activity of meropenem against OXA-48-producing strains, facilitating the achievement of lower MIC values upon addition of the inhibitor (23); (ii) the strong inhibitory activity of xeruborbactam against the OXA-48 enzyme, which is inhibited at very low Ki app values (in the nanomolar range) (24); and (iii) the antibacterial activity of xeruborbactam in Enterobacterales (18). Aztreonam/avibactam, ceftazidime/avibactam, and cefepime/taniborbactam also showed high activity against this subset of strains. As expected, imipenem/relebactam and meropenem/vaborbactam were the least effective combinations, as both relebactam and vaborbactam show very poor inhibitory activity against the OXA-48 enzyme (both combinations showed susceptibility rates around 80% against the whole subset of clinical OXA-48-producing Enterobacterales) (25). KPC-producing Enterobacterales represent a therapeutic target against which the greatest number of treatment options are available, as all inhibitors included in commercially available or investigational β-lactam/β-lactamase inhibitor combinations tested here effectively block this serine carbapenemase (26). In line with these findings, aztreonam/avibactam, meropenem/vaborbactam, imipenem/relebactam, cefepime/taniborbactam, and, to a lesser extent, ceftazidime/avibactam were highly active, with susceptibility rates ranging from 89% to 100%. However, meropenem/xeruborbactam once again proved to be the most active combination, demonstrating 100% susceptibility across all isolates. Interestingly, meropenem/xeruborbactam showed superior activity to carbapenem/β-lactamase inhibitor combinations such as imipenem/relebactam and meropenem/vaborbactam, which have been highlighted in recently available Infectious Diseases Society of America (IDSA) guidelines as promising options for combating high-inoculum KPC-producing Enterobacterales infections, such as ventilator-associated pneumonia, related to an increased risk of therapeutic failure and resistance development with ceftazidime/avibactam (27). Meropenem/xeruborbactam showed the greatest promise in the challenging therapeutic niche of MBL-producing Enterobacterales, with MIC50 and MIC90 values of ≤0.06 and 0.125 mg/L respectively, 100% susceptibility rates, and MICs ranging from ≤0.06 to 4 mg/L. The high activity was maintained irrespective of the specific MBL produced, although the potency was lower against MBL producers than against KPC or OXA-48 producers. Notably, meropenem/xeruborbactam has been shown to retain almost 100% activity against large collections of MBL-producing Enterobacterales strains in global surveys conducted between 2014 and 2017 (17). The present findings further support and extend these previous findings, demonstrating the continued effectiveness of meropenem/xeruborbactam against strains circulating between 2017 and 2024, including genetically diverse MBL-producing Enterobacterales. As observed in previous studies, some strains yielded MICs in the top range of susceptibility (4 mg/L). These elevated MICs have been previously associated with the production of MBL enzymes and disrupted porin channels, which together have been shown to reduce the potency of the combination by eight to 16 times (22). This observation is further corroborated by our E. coli HB4 experimental model, in which NDM-producing transformants with porin deficiency exhibited MICs of 4 mg/L. Aztreonam/avibactam and, to a lesser extent, cefepime/taniborbactam also displayed high activity against the MBL-producing strains included in this study. However, two strains showed decreased susceptibility or resistance to aztreonam/avibactam (MICs = 4-8 mg/L), and 18 strains were resistant to cefepime/taniborbactam (MICs = 8-64 mg/L), further emphasizing the need for developing xeruborbactam-based combinations to expand treatment options against MBL producers. Activity against clinical strains resistant to ceftazidime/avibactam, aztreonam/avibactam, and/or cefepime/taniborbactam The genotypic features and activity of meropenem/xeruborbactam against a panel of 14 clinical isolates carrying KPC amino acid variants are shown in Table 3. Most of these strains were recovered from patients who had previously received courses of treatment with ceftazidime/avibactam (data not shown), and in most cases, they belong to the worldwide scattered ST512 K. pneumoniae lineage, which became disseminated throughout Spain after its introduction from Italy in a large-scale outbreak that occurred in Southern Spain in 2012 (28). The panel was enriched with unduplicated variants in which the ceftazidime/avibactam resistance phenotype was driven by different alterations (substitutions, deletions, or large insertions) in different catalytic hot spots of the KPC architecture, including the classic Ω-loop, but also other distant regions, such as the 240-loop or the 270-loop (29). These strains were in all cases resistant to ceftazidime/avibactam (14/14; MICs = 16–>64 mg/L) and in some cases to cefepime/taniborbactam (5/14; MICs = 0.125–16 mg/L) or aztreonam/avibactam (1/14; MICs = 0.125–64 mg/L). Moreover, while ceftazidime/avibactam-resistant KPC variants are commonly associated with decreased activity against carbapenems, half of the strains producing these variants exhibited meropenem resistance (7/14) due to a disruption of OmpK35 and the classic GD insertion in OmpK36, a genetic hallmark of the ST512 lineage (6). Interestingly, the novel combinations meropenem/vaborbactam and imipenem/relebactam exhibited 100% susceptibility rates and high potency against all strains, particularly imipenem/relebactam, with MICs ranging from ≤0.06 to 2 mg/L and from ≤0.06 to 0.5 mg/L, respectively. However, meropenem/xeruborbactam outperformed these two combinations, with most strains yielding MICs of ≤0.06 mg/L (10/14) and in no case exceeding 0.25 mg/L. It is tempting to suggest that the increased potency of the meropenem/xeruborbactam combination against these strains may result from the following possible scenarios: (i) the combination takes advantage of including a carbapenem partner, against which these variants usually exhibit decreased hydrolytic activity (30), and (ii) xeruborbactam inhibits wild-type KPC enzymes at lower concentrations than vaborbactam and relebactam, and thus, the findings suggest that the increased potency is maintained against these variants (12). Altogether, these findings highlight meropenem/xeruborbactam as an attractive combination to combat strains showing KPC-mediated ceftazidime/avibactam resistance. TABLE 3 TABLE 3 Genotypic and phenotypic features of a collection of CPE producing different KPC variants against meropenem/xeruborbactam and comparator agents Isolate id Species MLST Resistance mechanismsa MIC (mg/L)b,c KPC β-lactamase KPC amino acid alteration Location in sequenced OmpK35 OmpK36 MEM (R > 8) M/X (R > 8) M/V (R > 8) I/R (R > 2) F/T (R > 4) C/A (R > 8) A/A (R > 4) 20220166 K. pneumoniae 512 KPC-23 V240A Loop 237-243 C66fs – 4 ≤0.06 ≤0.06 ≤0.06 0.125 16 0.25 231992 K. pneumoniae 512 KPC-28 del_242-243_GT Loop 237-243 C66fs ins_114_GD 1 ≤0.06 0.5 ≤0.06 16 >64 4 20211109 K. pneumoniae 512 KPC-31 D179Y Ω-loop C66fs – 2 ≤0.06 1 0.125 8 >64 0.5 KPLA K. pneumoniae 258 KPC-35 L169P Ω-loop C66fs ins_114_GD 1 ≤0.06 0.5 0.25 4 32 0.25 183111 K. pneumoniae 512 KPC-39 A172T Ω-loop C66fs ins_114_GD 16 0.125 2 0.25 4 64 1 183860 K. pneumoniae 512 KPC-47 A172T, T243A Ω-loop and loop 237-243 C66fs ins_114_GD 32 ≤0.06 0.5 0.5 4 >64 0.5 183358 K. pneumoniae 512 KPC-48 L169P, A172T Ω-loop C66fs ins_114_GD 8 0.25 1 0.5 8 >64 2 20220294 K. pneumoniae 512 KPC-66 del_168-169_EL Ω-loop C66fs ins_114_GD 4 0.25 1 0.25 1 32 0.125 202826 K. pneumoniae 512 KPC-85 A172V Ω-loop C66fs ins_114_GD 64 ≤0.06 1 0.125 4 32 0.5 171513 K. pneumoniae 512 KPC-94 L169H, del_170_N Ω-loop C66fs ins_114_GD 1 ≤0.06 1 0.125 2 >64 64 180510 K. pneumoniae 512 KPC-95 A172T, D179Y Ω-loop C66fs ins_114_GD 16 0.25 1 0.5 16 >64 4 20220366 K. pneumoniae 512 KPC-132 ins_270_KDDKSRAPN Loop 266-275 C66fs ins_114_GD 16 ≤0.06 2 0.25 4 >64 0.25 196228 K. pneumoniae 512 KPC-148 ins_275_EAVYTRAPNKDDKYS Loop 266-275 C66fs ins_114_GD 32 ≤0.06 1 0.125 8 >64 1 231595 K. pneumoniae 512 KPC-178 P174L Ω-loop C66fs ins_114_GD 32 ≤0.06 0.5 0.125 4 64 0.5 a –, not found; del: deletion of amino acids; fs: frameshift; ins: insertion of amino acids. b MEM: meropenem; M/X: meropenem/xeruborbactam; M/V: meropenem/vaborbactam; I/R: imipenem/relebactam; F/T: cefepime/taniborbactam; C/A: ceftazidime/avibactam; A/A: aztreonam/avibactam. c EUCAST breakpoints indicated for Enterobacterales. Clinical breakpoints for combinations that have not yet been approved (meropenem/xeruborbactam and cefepime/taniborbactam) were interpreted using those of the β-lactam partner. Avibactam, relebactam, and taniborbactam were tested at a fixed concentration of 4 mg/L, while vaborbactam and xeruborbactam were tested at 8 mg/L. d Location in KPC loops previously indicated by Hobson C. A. et al. AAC 2022 (31). Finally, a comprehensive analysis of the activity of meropenem/xeruborbactam against strains showing resistance to newly developed β-lactam/β-lactamase inhibitor combinations, along with their most relevant genotypic features, is summarized in Table 4. These strains comprised 18 Enterobacterales isolates (4 K. pneumoniae, 13 E. coli, and 1 Enterobacter cloacae complex) carrying different combinations of β-lactamases (including mostly MBLs or recently described inhibitor-resistant extended-spectrum β-lactamases (ESBLs), such as VEB-25) (32) in most cases combined with additional chromosomal mutations affecting porin channels, efflux pump activity, and, more importantly, the β-lactam target protein PBP3. The strains were commonly resistant to meropenem, meropenem/vaborbactam, imipenem/relebactam, and ceftazidime/avibactam, as they lack activity against MBL producers. More concerning, they yielded very high MICs for aztreonam/avibactam (15/18 resistant; MICs = 1–>64 mg/L) and cefepime/taniborbactam (14/18 resistant; MIC range = 1–>64 mg/L). Meropenem/xeruborbactam demonstrated 100% activity against this challenging panel, reducing the MIC of meropenem to values between ≤0.06 and 0.25 mg/L except for one K. pneumoniae isolate, which lacked carbapenemases but exhibited a disrupted OmpK36 (MIC = 4 mg/L). Probably, the most remarkable finding is that xeruborbactam restored the activity of meropenem against all E. coli isolates carrying the YRIN or YRIK tetra amino acid insertions in PBP3. Interestingly, this PBP3 alteration is increasingly described in high-risk carbapenemase-producing E. coli lineages and induces changes in the transpeptidase domain of the PBP enzyme. This alteration significantly reduces the activity of β-lactams whose spectrum of PBP blockade is highly restricted to PBP3, such as aztreonam and cefepime, and thus their respective combinations (33, 34). However, xeruborbactam can restore meropenem susceptibility against these strains because it is able to inactivate the underlying carbapenemase and because meropenem and xeruborbactam are able to target multiple PBPs in E. coli, thus bypassing the deleterious effect of PBP3 modifications on the antibacterial activity of aztreonam, cefepime, and their respective combinations (18, 35). Altogether, our findings provide an important baseline of in vitro data for the positioning of meropenem/xeruborbactam as a promising antibacterial combination for combating CPE, including emerging strains showing resistance to other newly developed β-lactam/β-lactamase inhibitor combinations, and argue for continuing its clinical development. TABLE 4 TABLE 4 Genotypic and phenotypic features of a collection of isolates showing emerging resistance mechanisms to newly developed β-lactam/β-lactamase inhibitor combinations against meropenem/xeruborbactam and comparator agents Isolate ID Species MLST Resistance mechanismsa MIC (mg/L) b,c Transferable Chromosomal Carbapenemases Other β-lactamases PBP3 insertion OmpF-liked OmpC-liked acrR ramR MEM (R > 8) M/X (R > 8) M/V (R > 8) I/R (R > 2) F/T (R > 4) C/A (R > 8) A/A (R > 4) R236 K. pneumoniae 14 VIM-1 SHV-5 – – ins_114_GD – M101fs 64 2 64 16 64 >64 8 N3418 K. pneumoniae 323 KPC-2 OXA-10, SHV-1, VEB-25 – – – – – 16 ≤0.06 ≤0.06 0.125 1 64 16 N3644 K. pneumoniae 37 – CMY-4, SHV-11 – – W125* – – 16 4 8 16 2 >64 >64 N3041 K. pneumoniae 1473 – DHA-1, TEM-1 – – – S215fs – 4 ≤0.06 1 0.125 16 2 >64 R5989 E. coli 471 NDM-5, OXA-181 CMY-42, CTX-M-15, TEM-1 YRIN – – – – 16 0.25 16 4 16 >64 16 R2222 E. coli 471 NDM-4 CMY-42, CTX-M-15, OXA-1, TEM-1 YRIK – – – – 8 ≤0.06 8 4 32 >64 16 N1416 E. coli 477 NDM-5 CTX-M-15, OXA-1, TEM-1 YRIK T263fs – – – 16 0.125 16 8 >64 >64 8 N1110 E. coli 471 – CMY-42, CTX-M-15 YRIK – – – – ≤0.06 ≤0.06 ≤0.06 0.125 4 4 >64 R460 E. coli 648e NDM-5 CMY-6, CTX-M-15 YRIN T263fs – – – 32 0.125 16 8 32 >64 8 N1606 E. coli 650 KPC-3, NDM-5 CMY-145, CTX-M-15, OXA-1, SHV-11, TEM-1 YRIN – – – – 64 0.125 32 4 64 >64 8 R461 E. coli 2 NDM-1 CMY-6 YRIN – – V29fs – 32 0.25 32 8 64 >64 16 R3033 E. coli 477 NDM-5 CMY-42-A171S, TEM-1 YRIK Y253fs – – – 16 ≤0.06 16 8 64 >64 16 R5987 E. coli 477 NDM-5 CMY-42-A171S, TEM-1 YRIK Y253fs – – – 16 ≤0.06 16 8 32 >64 16 N951 E. coli 477 NDM-5 CMY-42-A171S, TEM-1 YRIK Y253fs – – – 8 ≤0.06 8 8 64 >64 16 ARGA00338 E. coli 471 OXA-484 CMY-42, TEM-1 YRIN – – – – 0.125 ≤0.06 ≤0.06 0.125 1 4 4 AI2843 E. coli 410 NDM-5 CMY-2, CTX-M-15, OXA-1, TEM-1 YRIN – – – – 4 ≤0.06 4 8 16 >64 1 AI2858 E. coli 648 NDM-7 CMY-6, CTX-M-15, OXA-1 YRIN – – – – 8 ≤0.06 8 8 8 >64 4 N3046 E. cloacae complex 50 – ACT-15 – – – – – 2 0.125 1 0.5 16 8 8 a –, not found; *: stop codon; ins: insertion of amino acids; fs: frameshift; YRIN: four amino acid insertion of tyrosine-arginine-isoleucine-asparagine in the PBP3 codifying-sequence; YRIK: four amino acid insertion of tyrosine-arginine-isoleucine-lysine in the PBP3 codifying-sequence. b MEM: meropenem; M/X: meropenem/xeruborbactam; M/V: meropenem/vaborbactam; I/R: imipenem/relebactam; F/T: cefepime/taniborbactam; C/A: ceftazidime/avibactam; A/A: aztreonam/avibactam. c EUCAST breakpoints indicated for Enterobacterales. Clinical breakpoints for combinations that have not yet been approved (meropenem/xeruborbactam and cefepime/taniborbactam) were interpreted using those of the β-lactam partner. Avibactam, relebactam, and taniborbactam were tested at a fixed concentration of 4 mg/L, while vaborbactam and xeruborbactam were tested at 8 mg/L. d OmpF-like: OmpK35 for K. pneumoniae, OmpF for E. coli and OmpE35 for E. cloacae complex; OmpC-like: OmpK36 for K. pneumoniae, OmpC for E. coli, and OmpE36 for E. cloacae complex. e Could not be determined following Pasteur scheme. Assigned to ST648 following the Achtman scheme. MATERIALS AND METHODS Recombinant isolates In order to elucidate the specific impact of acquired β-lactamases circulating in Enterobacterales on meropenem/xeruborbactam and other broad-spectrum comparator β-lactam/β-lactamase inhibitor combinations (meropenem/vaborbactam, imipenem/relebactam, cefepime/taniborbactam, ceftazidime/avibactam, and aztreonam/avibactam) and also to examine the interaction between β-lactamase production and decreased outer membrane permeability on the activity of these combinations, we utilized a previously engineered library of E. coli recombinant isolates (36). For this work, the collection was enriched with 22 additional transformants, including producers of specific inhibitor-resistant β-lactamases. To this end, 11 new β-lactamase genes were cloned under conditions of wild-type (E. coli TG1) and low (E. coli HB4; OmpF- and OmpC-deficient) permeability, resulting in a final collection of 94 laboratory transformants. The genes blaVEB-25, blaBEL-1, blaSFO-1, blaVIM-4, blaIMP-8, blaIMP-23, blaSPM-1, blaCMH-7, blaAmpC (Enterobacter cloacae), blaAmpC (Klebsiella aerogenes), and blaOXA-1 were ligated to the pUCP-24 plasmid and electroporated into both E. coli hosts. The isolates were selected on Luria-Bertani (LB) agar plates containing 10 mg/L gentamicin. All transformants were confirmed by PCR, plasmid restriction analysis, Sanger sequencing, and MIC determination. Clinical isolates This study included a representative collection of 300 non-duplicated clinical isolates of CPE recovered from patients admitted to 39 Spanish hospitals across 13 different Spanish regions during the period 2017–2024. The strains were collected by researchers from three reference laboratories in Northern, Central, and Southern Spain, each involved in a distinct large-scale surveillance initiative: (i) the Carbapenem-Resistant Enterobacterales, Genome Database Project (Microbiology Department, Complexo Hospitalario Universitario A Coruña, A Coruña) (37); (ii) the Spanish Reference Laboratory for Research in Antibiotic Resistance and Healthcare-associated Infections, Centro Nacional de Microbiología, Madrid (38); and (iii) the Andalusian Reference PIRASOA Surveillance Program for the Prevention and Control of Healthcare-Associated Infections (PIRASOA Reference Laboratory, Hospital Universitario Virgen Macarena, Seville) (39). From the collections obtained in these three reference laboratories, the final selection of isolates evaluated here included at least 100 representatives of each of the three main types of circulating carbapenemases (OXA-48-like, KPC-like, and MBLs). The 300 isolates were selected by a detailed selection process aimed at maximizing the diversity of bacterial species, multi-locus sequence types, and β-lactamase content, to guarantee the representativeness of the collection. A summary and detailed list of the isolates (including bacterial species, sequence types and β-lactamase content are available at Tables S1 to S5). In these three centers, preliminary characterization of carbapenemase production was carried out using phenotypic methods (such as the modified carbapenem inactivation method [mCIM] and Carba NP tests) and molecular techniques (PCR and Sanger sequencing). The bacterial species, sequence type, and carbapenemase content were further confirmed by WGS using short-read Illumina technology. All clinical strains and their corresponding FASTQ files were centralized at a reference center (Microbiology Department, Complexo Hospitalario Universitario A Coruña) for antimicrobial susceptibility testing and detailed WGS resistome analysis (described below). Additionally, two challenging sets of strains previously collected by researchers and exhibiting emerging resistance mechanisms to β-lactams were included: (i) a collection of 14 K. pneumoniae isolates carrying KPC β-lactamase variants associated with high-level ceftazidime/avibactam resistance, most of which were recovered from patients previously treated with this combination, and (ii) a collection of 18 clinical Enterobacterales isolates from different bacterial species, exhibiting various emerging resistance mechanisms (e.g., PBP3 insertions and other chromosomal alterations in combination with MBLs or inhibitor-resistant ESBLs) associated with resistance or decreased susceptibility to new combinations with activity against metallo-β-lactamases, specifically aztreonam/avibactam and/or cefepime/taniborbactam (40). Resistance genomics For strains that had already been sequenced, paired-end Illumina reads were sent to the reference laboratory for analysis, and the other strains were sequenced ad hoc on an Illumina platform for this study. Briefly, the quality control of all paired-end Illumina reads was performed using fastp (v.0.32.2) (41) and BMTagger (v.3.1) (42). Genome assembly was carried out with Unicycler (v.0.5.0) (43). To assess quality, completeness, and the absence of contamination, the assembled genomes were analyzed with CheckM (v.1.1.3) (44). Species were identified using Kmerfinder (v.3.2) (45) and multilocus sequence typing (MLST) (Center for Genomic Epidemiology, v.2.0) (46). Putative open reading frames were annotated with Bakta (v.1.7.0) (47), and horizontally acquired resistance determinants were characterized using Resistance Gene Identifier (RGI) (v.5.2.0) and Comprehensive Antibiotic Resistance Database (CARD) (v.3.2.8) (48). For isolates producing KPC β-lactamase variants, amino acid sequence variation in the KPC enzymes was manually analyzed using BLAST (49). KPC amino acid numbering followed the Ambler scheme. For isolates showing emerging resistance mechanisms to aztreonam/avibactam and cefepime/taniborbactam, the presence of chromosomal mutations in genes encoding PBPs, porins, efflux pump regulators, and iron uptake-related genes was further analyzed by variant calling with Snippy (v.4.6.0) (50), and using the genome of the β-lactam susceptible strains K. pneumoniae ATCC 10031, E. coli ATCC 25922 and E. cloacae ATCC 13047 as references. Natural missense mutations identified in classical chromosomal genes previously associated with β-lactam resistance (e.g., mrdA, ftsI, ramA, marA, acrR, and tolC) were reviewed and filtered out after screening a representative collection of CPE with a wild-type antimicrobial susceptibility profile toward identifying new β-lactam/β-lactamase inhibitor combinations. Antimicrobial susceptibility testing MICs of meropenem, meropenem/xeruborbactam, meropenem/vaborbactam, imipenem, imipenem/relebactam, cefepime, cefepime/taniborbactam, ceftazidime, ceftazidime/avibactam, aztreonam, and aztreonam/avibactam were determined in triplicate by reference broth microdilution assays with cation-adjusted Müeller-Hinton broth prepared according to Clinical and Laboratory Standards Institute (CLSI) M100 guidelines (51). Except for meropenem/xeruborbactam, the MICs of the β-lactam partner for the different β-lactam/β-lactamase inhibitor combinations are not shown throughout the results for conciseness but are provided in Tables S3 to S5. MIC values were interpreted following European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines (v.14.0) for Enterobacterales (https://www.eucast.org/clinical_breakpoints). Clinical breakpoints for combinations that have not yet been approved were interpreted using those of the β-lactam partner. Avibactam, relebactam, and taniborbactam were tested at a fixed concentration of 4 mg/L, while vaborbactam and xeruborbactam were tested at 8 mg/L. Reference strains E. coli ATCC 25922, K. pneumoniae ATCC 700603, E. coli NCTC 13353, and Acinetobacter baumannii NCTC 13304 (for cephalosporin/β-lactamase inhibitor combinations), and K. pneumoniae ATCC BAA-2814 (for carbapenem/β-lactamase inhibitor combinations) were used as controls for comparative purposes. ACKNOWLEDGMENTS This work was supported by the Instituto de Salud Carlos III (ISCIII projects PI23/00851, PI22/01212, PI21/00704, PI20/01212, and PI20/01749) and co-funded by the European Union. The research was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC; CB21/13/00055, CB21/13/00012, CB21/13/00049, and CB21/13/00095), integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013-2016, and funded by the ISCIII-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe.” The study was also funded by Axencia Galega de Innovacion (GAIN), Conselleria de Innovacion, Conselleria de Emprego e Industria through “Proxectos de excelencia” (IN607D 2021/12 to A.B. and IN607D 2024/008 to J.A.-S.), and ‘’Axudas para a consolidación de grupos de investigación que pola súa produción científica e a súa actividade de I + D constitúan unha referencia no Sistema galego de I + D + I’’ (IN607A 2024/09 to G.B.). L.S.-P. was financially supported by Fundación Pública Galega de Investigación Biomédica (INIBIC) and Xunta de Galicia (IN606A 2024/022). S.R.-P. was financially supported by the Río Hortega Program (ISCIII, CM23/00104). T.B.-M. was financially supported by the Río Hortega Program (ISCIII, CM23/00095). L.G.-P. was financially supported by the PFIS Program (ISCIII, FI23/00074). J.A.-S. was financially supported by the Juan Rodés Program (ISCIII, JR21/00026).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Antimicrobial activity of Cefiderocol against the Carbapenemase-producing Enterobacter cloacae complex and characterization of reduced susceptibility associated with Metallo-β-Lactamase VIM-1

  • Lasarte-Monterrubio, Cristina
  • Guijarro-Sánchez, Paula
  • Vázquez-Ucha, Juan Carlos
  • Alonso-García, Isaac
  • Álvarez-Fraga, Laura
  • Outeda-García, Michelle
  • Martínez Guitián, Marta
  • Peña-Escolano, Andrea
  • Maceira, Romina
  • Lence, Emilio
  • González-Bello, Concepción
  • Arca-Suárez, Jorge
  • Bou, Germán
  • Beceiro Casas, Alejandro
[Abstract] Emergence of cefiderocol resistance among carbapenemase-producing Enterobacterales, particularly those in the Enterobacter cloacae complex (ECC), is becoming of alarming concern; however, the mechanistic basis of this phenomenon remains poorly understood. We describe the acquisition of VIM-1-mediated reduced cefiderocol susceptibility (MICs 0.5 to 4 mg/L) in a collection of 54 carbapenemase-producing isolates belonging to the ECC. MICs were determined by reference methodologies. Antimicrobial resistance genomic analysis was performed through hybrid WGS. The impact of VIM-1 production on cefiderocol resistance in the ECC background was examined at microbiological, molecular, biochemical, and atomic levels. Antimicrobial susceptibility testing yielded 83.3% susceptible isolates and MIC50/90 values of 1/4 mg/L. Decreased susceptibility to cefiderocol was mainly associated with isolates producing VIM-1, with cefiderocol MICs 2- to 4-fold higher than for isolates carrying other types of carbapenemases. E. cloacae and Escherichia coli VIM-1 transformants displayed significantly enhanced cefiderocol MICs. Biochemical assays with purified VIM-1 protein revealed low but detectable cefiderocol hydrolysis. Simulation studies revealed how cefiderocol is anchored to the VIM-1 active site. Additional molecular assays and WGS data analysis highlighted the implication of SHV-12 coproduction and suggested the inactivation of the FcuA-like siderophore receptor as further contributors to the higher cefiderocol MICs. Our findings warn of the potential of the VIM-1 carbapenemase to at least partly limit the activity of cefiderocol in the ECC. This effect is probably enhanced due to combination with additional mechanisms, such as ESBL production and siderophore inactivation, and indicates the need for active surveillance to extend the life span of this promising cephalosporin., This research was supported by Projects PI17/01482 and PI20/01212 awarded to AB, PI22/01212 to JAS and PI18/00501 to GB, within in the National Plan for Scientific Research, Development and Technological Innovation 2017 to 2020 and funded by the ISCIII-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe.” The work was also supported by CIBERINFEC (CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III). The study was also funded by project IN607A 2020/05 (GAIN-Agencia Gallega de Innovación-Consellería de Economía, Emprego e Industria) awarded to GB and project IN607D 2021/12 awarded to AB. It was also supported by Planes Nacionales de I+D+i2017 to 2020 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) cofinanced by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth2014 to 2020. J.A.-S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026), J.C.V.-U. was financially supported by IN606B-2022/009 Grant (Xunta de Galicia), C.L.-M. was financially supported by IN606A-2019/029 Grant (Xunta de Galicia) and PGS was financially supported by IN606A 2021/021 Grant (Xunta de Galicia). M.O. was financially supported by IN607D 2021/12 (Xunta de Galicia). I.A.-G. was financially supported by the Rio Hortega program (ISCIII, CM21/00076). C.G.-B. acknowledges financial support from the Spanish Ministry of Science and Innovation (PID2019-105512RB-I00), the Xunta de Galicia (ED431C 2021/29 and the Centro singular de investigación de Galicia accreditation2019 to 2022 [ED431G 2019/03]), and the European Regional Development Fund (ERDF)., Xunta de Galicia; IN607A 2020/05, Xunta de Galicia; IN607D 2021/12, Xunta de Galicia; IN606B-2022/009, Xunta de Galicia; IN606A-2019/029, Xunta de Galicia; IN606A 2021/021, Xunta de Galicia; ED431C 2021/29, Xunta de Galicia; ED431G 2019/03
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Epidemiology, resistance genomics and susceptibility of Acinetobacter species: results from the 2020 Spanish nationwide surveillance study

  • Lasarte-Monterrubio, Cristina
  • Guijarro, Paula
  • Alonso-García, Isaac
  • Outeda-García, Michelle
  • Maceiras, Romina
  • González-Pinto, Lucía
  • Martínez Guitián, Marta
  • Fernández-Lozano, Carlos
  • Vázquez-Ucha, Juan Carlos
  • Bou, Germán
  • Arca-Suárez, Jorge
  • Beceiro Casas, Alejandro
[Abstract]: Background: As increasing antibiotic resistance in Acinetobacter baumannii poses a global healthcare challenge, understanding its evolution is crucial for effective control strategies. Aim: We aimed to evaluate the epidemiology, antimicrobial susceptibility and main resistance mechanisms of Acinetobacter spp. in Spain in 2020, and to explore temporal trends of A. baumannii. Methods: We collected 199 single-patient Acinetobacter spp. clinical isolates in 2020 from 18 Spanish tertiary hospitals. Minimum inhibitory concentrations (MICs) for nine antimicrobials were determined. Short-read sequencing was performed for all isolates, and targeted long-read sequencing for A. baumannii. Resistance mechanisms, phylogenetics and clonality were assessed. Findings on resistance rates and infection types were compared with data from 2000 and 2010. Results: Cefiderocol and colistin exhibited the highest activity against A. baumannii, although colistin susceptibility has significantly declined over 2 decades. A. non-baumannii strains were highly susceptible to most tested antibiotics. Of the A. baumannii isolates, 47.5% (56/118) were multidrug-resistant (MDR). Phylogeny and clonal relationship analysis of A. baumannii revealed five prevalent international clones, notably IC2 (ST2, n = 52; ST745, n = 4) and IC1 (ST1, n = 14), and some episodes of clonal dissemination. Genes blaOXA-23, blaOXA-58 and blaOXA-24/40 were identified in 49 (41.5%), eight (6.8%) and one (0.8%) A. baumannii isolates, respectively. ISAba1 was found upstream of the gene (a blaOXA-51-like) in 10 isolates. Conclusions: The emergence of OXA-23-producing ST1 and ST2, the predominant MDR lineages, shows a pivotal shift in carbapenem-resistant A. baumannii (CRAB) epidemiology in Spain. Coupled with increased colistin resistance, these changes underscore notable alterations in regional antimicrobial resistance dynamics., This work was supported by Projects PI20/01212 and PI23/00851 awarded to AB, Project PI21/00704 awarded to GB, and Project PI22/01212 awarded to JA-S, funded by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. The work was also supported by CIBER-Consorcio Centro de Investigación Biomédica en Red- de Enfermedades Infecciosas, Instituto de Salud Carlos III (CB21/13/00055), Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU and by project IN607A 2020/05 (GAIN-Agencia Gallega de InnovaciónConsellería de Economía, Emprego e Industria) awarded to GB and project IN607D 2021/12 awarded to AB. JA-S was financially supported by the Juan Rodés program (ISCIII, JR21/00026), JCV-U was financially supported by IN606B-2022/009 (Xunta de Galicia), CL-M was financially supported by PI20/01212 (ISCIII), PG-S was financially supported by IN606A 2021/021 Grant (Xunta de Galicia). MO was financially supported by IN607D 2021/12. IA-G was financially supported by the Rio Hortega program (ISCIII, CM21/00076). MM-G was financially supported by RSU.UDC.M505 (Ministerio de Universidades)., Xunta de Galicia; IN607A 2020/05, Xunta de Galicia; IN607D 2021/12, Xunta de Galicia; IN606B-2022/009, Xunta de Galicia; IN606A 2021/021, Xunta de Galicia; IN607D 2021/12, Universidade da Coruña; RSU.UDC.M505
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Functional and structural analyses of amino acid sequence variation in PDC β-lactamase reveal different mechanistic pathways toward cefiderocol resistance in Pseudomonas aeruginosa

  • González-Pinto, Lucía
  • Gomis-Font, María Antonia
  • Lence, Emilio
  • Outeda-García, Michelle
  • Blanco Martín, Tania
  • Rodríguez-Pallares, Salud
  • Sánchez-Peña, Lucía
  • Alonso-García, Isaac
  • Vázquez-Ucha, Juan Carlos
  • Beceiro Casas, Alejandro
  • Bou, Germán
  • González-Bello, Concepción
  • Oliver, Antonio
  • Arca-Suárez, Jorge
[Abstract] A wide variety of clinically observed amino acid alterations in the Pseudomonas aeruginosa chromosomal β-lactamase AmpC (Pseudomonas-derived cephalosporinase [PDC]) are associated with increased resistance to cefepime, ceftolozane/tazobactam, or ceftazidime/avibactam, but their impact on cefiderocol resistance is unclear. We took advantage of a previously engineered collection of wild-type (PAO1) and iron uptake-deficient (PAO ΔpiuC) P. aeruginosa isolates producing 19 distinct PDC variants with substitutions in key catalytic regions. While most variants had moderate effects on cefiderocol minimum inhibitory concentrations compared to PDC-1, the E219K (Ω-loop) and L293P (helix H10) variants significantly affected cefiderocol activity. Kinetic studies revealed that both mutations improve cefiderocol hydrolysis through different enzymatic mechanisms compared to PDC-1 (Km = 85.29 µM, kcat = 0.0036 s-1, and kcat/Km = 0.00004 µM-1 s-1), leading to enhanced turnover in PDC E219K (Km = 465.64 µM, kcat = 0.45 s-1, and kcat/Km = 0.00096 µM-1 s-1) and improved affinity in PDC L293P (Km = 2.69 µM, kcat = 0.0036 s-1, and kcat/Km = 0.00135 µM-1 s-1). These mechanisms are also involved in resistance to ceftolozane and cefepime, identified as the preferred substrates for the E219K and L293P variants, respectively. Molecular dynamics (MD) simulation studies revealed that (i) rigidification of the Ω-loop in PDC E219K promotes optimal accommodation of the R1 group of cefiderocol, enhancing nucleophilic attack by the catalytic serine; (ii) the less folded conformation of helix H10 in PDC L293P improves cefiderocol accommodation in the active site by establishing stronger hydrogen-bonding interactions with the R2 group. Our findings demonstrate that the PDC β-lactamase may take advantage of the structural similarities between cefiderocol and other cephalosporins and accelerate hydrolysis by accommodating the E219K or L293P amino acid replacements., This study was supported by the Instituto de Salud Carlos III (ISCIII), through projects PI20/01212, PI21/00704, PI22/01212, and PI23/00851, and co-funded by the European Union. The research was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CB21/13/00055 and CB21/13/00099). Funding was also provided by Axencia Galega de Innovación (GAIN), Consellería de Innovación and Consellería de Economía, Emprego e Industria, Xunta de Galicia (IN607D 2021/12 to A.B., IN607A 2016/22 to G.B., and IN607D 2024/008 to J.A.-S.), the Spanish State Agency of Research (PID2022-136963OB-I00/AEI/10.13039/501100011033 to C.G.-B.), the Xunta de Galicia (ED431C 2021/29 and Centro Singular de Investigación de Galicia accreditation 2024–2027 [ED431G 2023/03] to C.G.-B.), and the European Regional Development Fund. All authors are grateful to the Centro de Supercomputación de Galicia for the use of the Finis Terrae computer. We gratefully acknowledge the Fundación Pública Galega de Investigación Biomédica INIBIC for their financial support in covering the article processing charges. L.G.-P. was financially supported by the ISCIII PFIS program (FI23/00074). M.A.G.-F. was financially supported by the ISCIII PFIS program (FI22/00039). M.O.-G. was financially supported by GAIN-Xunta de Galicia (IN606A 2023/023). T.B.-M. was financially supported by the ISCIII Río Hortega program (CM23/00095). S.R.-P. was financially supported by the ISCIII Río Hortega program (CM23/00104). L.S.-P. was financially supported by GAIN-Xunta de Galicia (IN606A 2024/022). I.A.-G. was financially supported by the ISCIII Juan Rodés program (JR23/00036). J.C.V.-U. was financially supported by GAIN-Xunta de Galicia (IN606B 2022/009). J.A.-S. was financially supported by the ISCIII Juan Rodés program (JR21/00026). The funders had no role in the study design, data collection and interpretation, or the decision to submit the work for publication.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Emergence of KPC-8-producing K. pneumoniae infection without prior exposure to ceftazidime/avibactam: the threat of de novo infections by ceftazidime/avibactam-resistant KPC variants

  • Mateo-Vargas, María Alejandra
  • Rodríguez-Pallares
  • Arca-Suárez, Jorge
  • López-Cerero, Lorena
  • Rodríguez-Iglesias, Manuel
  • Galán-Sánchez, Fátima
[Data availability] This Whole Genome Shotgun project has been deposited at DDBJ/ENA/GenBank under the Bioproject accession number PRJNA1026946., De novo infections caused by ceftazidime/avibactam-resistant KPC variants are rarely reported. We characterize the evolution of a KPC-8-producing Klebsiella pneumoniae strain involved in a primary infection without previous ceftazidime/avibactam treatment. During a 15-month follow-up, changes in carbapenem susceptibility due to porin alterations were observed, remaining susceptible to meropenem/vaborbactam, imipenem/relebactam, and cefiderocol. High- and low-permeability recombinant Escherichia coli isolates analysis revealed that, unlike the widespread ceftazidime/avibactam-resistant variant KPC-31, KPC-8 confers ceftazidime/avibactam resistance without decreasing carbapenemase activity., This study was supported by Menarini, with funding directly provided to the institution. This work was also supported by the Instituto de Salud Carlos III through project PI22/01212, by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC, CB21/13/00055), integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016, by the ISCIII-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe” and by the Axencia Galega de Innovación (GAIN), Consellería de Innovación, Consellería de Emprego e Industria through “Proxecto de excelencia” IN607D2024/008 to J.A.-S. and co-funded by the European Union. S.R.-P. was financially supported by the Río Hortega program (ISCII, CM23/00104). J.A.-S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026). Conceptualization and methodology: F.G-.S., M.R.-I., and J.A.-S. Software and formal analysis: M.A.M.-V., S.R.-P., and L.L.-C. Investigation and validation: M.A.M.-V., J.A.-S., and S.R.-P. Resources: F.G.-S., M.R.-I., L.L.-C., and J.A.-S. Data curation: M.A.M.-V. Writing—original draft: M.A.M.-V., F.G.-S., and S.R.-P. Writing—review and editing: all authors. Visualization: M.A.M.-V., F.G.-S., J.A.-S., and L.L.-C. Supervision: all authors. Project administration: F.G.-S. and M.R.-I. Funding acquisition: F.G.-S., J.A.-S., and S.R.-P. All authors amended and approved the final version of the manuscript., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations

  • Sánchez-Peña, Lucía
  • Rodríguez-Pallares, Salud
  • Aja-Macaya, Pablo
  • Blanco-Martín, Tania
  • González-Pinto, Lucía
  • Pérez-Rodríguez, Gloria
  • Le Terrier, Christophe
  • Portillo-Calderón, Inés
  • Recacha, Esther
  • Riazzo, Cristina
  • Vázquez-Ucha, Juan Carlos
  • Beceiro, Alejandro
  • Aracil, Belén
  • Oteo-Iglesias, Jesús
  • Martínez-Martínez, Luis
  • Poirel, Laurent
  • Bou, Germán
  • Arca-Suárez, Jorge
Xeruborbactam is a broad-spectrum boronate-type β-lactamase inhibitor. We aimed to evaluate its activity in combination with meropenem and compare it with other β-lactam/β-lactamase inhibitor combinations against Enterobacterales. The following isolates were screened: (i) an isogenic collection of 94 Escherichia coli isolates producing β-lactamases under wild-type and low-permeability conditions, (ii) 300 genetically diverse clinical Enterobacterales isolates producing the three main carbapenemase types (KPC-like, OXA-48-like, and metallo-β-lactamases), and (iii) two collections of isolates producing mechanisms of resistance to β-lactam/β-lactamase inhibitor combinations, such as KPC variants or PBP3 insertions combined with metallo-β-lactamases (MBLs). The MICs of meropenem, meropenem/xeruborbactam, meropenem/vaborbactam, imipenem, imipenem/relebactam, cefepime, cefepime/taniborbactam, ceftazidime, ceftazidime/avibactam, aztreonam, and aztreonam/avibactam were determined by reference broth microdilution and interpreted following the European Committee on Antimicrobial Susceptibility Testing guidelines, using the breakpoint of the β-lactam alone for not yet approved combinations. Resistance mechanisms of all clinical isolates were analyzed by whole genome sequencing. Meropenem/xeruborbactam had the broadest spectrum against the isogenic collection, although higher MICs were noted for transformants producing IMP-23, SPM-1, and NDM enzymes (these latter only when produced under low-permeability conditions). Meropenem/xeruborbactam displayed the most potent activity against the collection of 300 clinical strains (MIC50/90 ≤0.06/≤0.06 mg/L). Xeruborbactam restored meropenem activity against the strains carrying resistance mechanisms to β-lactam/β-lactamase inhibitor combinations, including strains producing KPC variants or MBLs in combination with additional chromosomal alterations (MIC range: ≤0.06–0.25 and ≤0.06–4 mg/L, respectively). Our findings highlight the potential of xeruborbactam in combination with meropenem as a promising treatment against carbapenemase-producing Enterobacterales, including strains with emerging resistance to other β-lactam/β-lactamase inhibitor combinations., This work was supported by the Instituto de Salud Carlos III (ISCIII projects PI23/00851, PI22/01212, PI21/00704, PI20/01212, and PI20/01749) and co-funded by the European Union. The research was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC; CB21/13/00055, CB21/13/00012, CB21/13/00049, and CB21/13/00095), integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013-2016, and funded by the ISCIII-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe.” The study was also funded by Axencia Galega de Innovacion (GAIN), Conselleria de Innovacion, Conselleria de Emprego e Industria through “Proxectos de excelencia” (IN607D 2021/12 to A.B. and IN607D 2024/008 to J.A.-S.), and ‘’Axudas para a consolidación de grupos de investigación que pola súa produción científica e a súa actividade de I + D constitúan unha referencia no Sistema galego de I + D + I’’ (IN607A 2024/09 to G.B.). L.S.-P. was financially supported by Fundación Pública Galega de Investigación Biomédica (INIBIC) and Xunta de Galicia (IN606A 2024/022). S.R.-P. was financially supported by the Río Hortega Program (ISCIII, CM23/00104). T.B.-M. was financially supported by the Río Hortega Program (ISCIII, CM23/00095). L.G.-P. was financially supported by the PFIS Program (ISCIII, FI23/00074). J.A.-S. was financially supported by the Juan Rodés Program (ISCIII, JR21/00026)., Peer reviewed